Filed Pursuant to Rule 424(b)(5)
Registration No. 333-218608
PROSPECTUS SUPPLEMENT
(To Prospectus dated June 23, 2017)
3,000,000 Shares of Common Stock
We are offering 3,000,000 shares of our common stock, $0.01 par value per share, at a purchase price of $0.70
per share, to certain institutional investors. In a concurrent private placement, we are also offering to such investors, warrants
to purchase up to 3,000,000 shares of our common stock (the “
Warrants
”), with an exercise price of $0.75 per
share. The Warrants and the shares of our common stock issuable upon the exercise of the Warrants (the “
Warrant Shares
”) are being offered pursuant to the exemption provided in Section 4(a)(2) under the Securities Act of 1933, as
amended (the “
Securities Act
”) and Rule 506(b) promulgated thereunder, and they are not being offered
pursuant to this prospectus supplement and the accompanying prospectus. The Warrants being issued in the concurrent private placement
are not listed on any securities exchange, and we do not expect to list the Warrants.
Our common stock is listed on the Nasdaq Capital Market and traded under the symbol “CUR” The
last reported sale price of our common stock on the Nasdaq Capital Market on October 24, 2018 was $0.753 per share.
As of October 24, 2018, the aggregate market value of the outstanding common stock held by non-affiliates,
computed by reference to the price at which our common stock was last sold on September 4, 2018 was $15,710,114, based on 15,205,060
shares of our outstanding common stock as of October 24, 2018, of which 12,772,450 shares were held by non-affiliates. During the
12 calendar months prior to and including the date of this prospectus (excluding this offering), we have not sold any securities
pursuant to General Instruction I.B.6 of Form S-3.
Investing in our securities involves a high degree of risk.
See the section entitled “Risk Factors” appearing on pages S-7 of this prospectus supplement and elsewhere in
this prospectus supplement and the accompanying base prospectus for a discussion of information that should be considered in
connection with an investment in our securities.
We have retained H.C. Wainwright & Co., LLC (“Wainwright”)
to act as our exclusive placement agent in connection with the offer and sale of the shares of our common stock. The placement
agent has agreed to use its reasonable best efforts to sell the shares of common stock offered by this prospectus supplement and
the accompanying prospectus. We have agreed to pay the placement agent the placement agent fees set forth in the table below, which
assumes that we sell all of the shares of common stock we are offering.
|
|
|
Per Share
|
|
Total
|
|
Offering Price
|
|
$
|
0.70
|
|
|
$
|
2,100,000
|
|
|
Placement Agent Fees(1)(2)
|
|
$
|
0.049
|
|
|
$
|
147,000
|
|
|
Proceeds, before expenses, to us(2)
|
|
$
|
0.651
|
|
|
$
|
1,953,000
|
|
(1)
In addition, we have agreed to reimburse the placement agent for certain of its expenses and to grant warrants to purchase shares
of our common stock to the placement agent as described under the “Plan of Distribution” on page S-12 of this
prospectus supplement (the “
Placement Agent Warrants
”).
(2) The
amount of the offering proceeds to us presented in this table does not give effect to the exercise, if any, of the Warrants being
issued in the concurrent private placement or of the Placement Agent Warrants.
Neither the Securities and Exchange Commission nor any state securities commission
has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus supplement or the accompanying
prospectus. Any representation to the contrary is a criminal offense.
We anticipate delivery of the shares will take place on or about October 29, 2018,
subject to the satisfaction of certain closing conditions.
H.C. Wainwright & Co.
The date of this prospectus supplement is October 25, 2018.
TABLE OF CONTENTS
Prospectus Supplement
Prospectus
ABOUT THIS PROSPECTUS SUPPLEMENT
This prospectus supplement is part of the registration statement
on Form S-3 (File No. 333-218608) that we filed with the Securities and Exchange Commission, or the SEC, using a “shelf”
registration process to register sales of our securities under the Securities Act of 1933, as amended, or the Securities Act. This
document consists of two parts. The first part is this prospectus supplement, including the documents incorporated by reference,
which describes the specific terms of this offering. The second part is the accompanying prospectus filed with the SEC as part
of the registration statement that was declared effective by the SEC on June 23, 2017, including the documents incorporated by
reference, that gives more general information, some of which may not apply to this offering. Generally, when we refer only to
the “prospectus,” we are referring to both parts combined.
This prospectus supplement may add to, update or change information
in the accompanying prospectus and the documents incorporated by reference into this prospectus supplement or the accompanying
prospectus. To the extent there is a conflict between the information contained in this prospectus supplement and the accompanying
prospectus, you should rely on information contained in this prospectus supplement, provided that if any statement in, or incorporated
by reference into, one of these documents is inconsistent with a statement in another document having a later date, the statement
in the document having the later date modifies or supersedes the earlier statement. Any statement so modified will be deemed to
constitute a part of this prospectus only as so modified, and any statement so superseded will be deemed not to constitute a part
of this prospectus.
We sometimes refer to the shares of common stock offered hereby
as the “securities” or “Shares”.
This prospectus supplement, the accompanying prospectus and the
documents incorporated into each by reference include important information about us, the securities being offered and other information
you should know before investing in our securities. You should also read and consider information in the documents to which we
have referred you in the section of this prospectus supplement entitled “Where You Can Find More Information.”
You should rely only on this prospectus supplement, the accompanying
prospectus and the information incorporated or deemed to be incorporated by reference in this prospectus supplement and the accompanying
prospectus as well as any free writing prospectus. We and the underwriters have not authorized anyone to provide you with information
that is in addition to or different from that contained or incorporated by reference in this prospectus supplement and the accompanying
prospectus. If anyone provides you with different or inconsistent information, you should not rely on it. This prospectus supplement,
the accompanying prospectus and any related free writing prospectus do not constitute an offer to sell or the solicitation of an
offer to buy securities in any jurisdiction to any person to whom it is unlawful to make such offer or solicitation in such jurisdiction.
You should not assume that the information contained or incorporated by reference in this prospectus supplement or the accompanying
prospectus is accurate as of any date other than as of the date of this prospectus supplement or the accompanying prospectus, as
the case may be, or in the case of the documents incorporated by reference, the date of such documents regardless of the time of
delivery of this prospectus supplement and the accompanying prospectus or any sale of our securities. Our business, financial condition,
liquidity, results of operations and prospects may have changed since those dates.
We further note that the representations, warranties and covenants
made by us in any agreement that is filed as an exhibit to any document that is incorporated by reference into this prospectus
supplement or the accompanying prospectus were made solely for the benefit of the parties to such agreement, including, in some
cases, for the purpose of allocating risk among the parties to such agreements, and should not be deemed to be a representation,
warranty or covenant to you. Moreover, such representations, warranties or covenants were accurate only as of the date when made.
Accordingly, such representations, warranties and covenants should not be relied on as accurately representing the current state
of our affairs.
The industry and market data contained or incorporated by reference
in this prospectus supplement and the accompanying prospectus are based either on our management’s own estimates or on independent
industry publications, reports by market research firms or other published independent sources. Although we believe that such
data contained herein from such sources is reliable, there can be no assurance or guarantee as to the accuracy or completeness
of the information obtained from these sources. Unless otherwise indicated, all information contained or incorporated by reference
in this prospectus supplement and the accompanying prospectus concerning our industry in general or any segment thereof, including
information regarding our general expectations and market opportunity, is based on management’s estimates using internal
data, data from industry related publications, consumer research and marketing studies and other externally obtained data.
PROSPECTUS SUPPLEMENT SUMMARY
This summary highlights selected information appearing elsewhere in this
prospectus supplement or in the accompanying prospectus or incorporated by reference into this prospectus supplement and the accompanying
prospectus and does not contain all of the information that may be important to you or that you should consider before investing
in our securities. Before making an investment decision, you should read this prospectus supplement, the accompanying prospectus
and the information incorporated by reference in this prospectus supplement and the accompanying prospectus in their entirety,
including “Risk Factors” beginning on page S-7 of this prospectus supplement.
As used in this prospectus supplement, unless context otherwise requires,
the words “we,” “us,” “our,” “the Company,” “Neuralstem” and “Registrant”
refer to Neuralstem, Inc. and its subsidiary. Also, any reference to “common share” or “common stock,”
refers to our $0.01 par value common stock. Additionally, any reference to “Series A Preferred Stock” refers to our
Series A 4.5% Convertible Preferred Stock.
Our Business
Overview
We are focused on the research and development of nervous system
therapies based on our proprietary human neural stem cells and our small molecule compounds with the goal of gaining approval from
the United States Food and Drug Administration or FDA, and its international counterparts, to market and commercialize such therapies.
We are headquartered in Germantown, Maryland.
Our patented technology platform has three core components:
-
Over 300 lines of human, regionally specific neural stem cells,
some of which we believe have the potential to be used to treat serious or life-threatening diseases through direct transplantation
into the central nervous system;
-
Proprietary screening capability – our ability to generate
human neural stem cell lines provides a platform for chemical screening and discovery of novel compounds; and
-
Small molecules that have resulted from Neuralstem’s neurogenesis
screening platform that we believe may have the potential to treat wide variety of nervous system conditions.
Our technology platform to date has produced two lead assets in
clinical development: our NSI-189 phosphate small molecule program and NSI-566 stem cell therapy program.
We have developed and maintain what we believe is a strong portfolio
of patents and patent applications that form the proprietary base for our research and development efforts. We own or exclusively
license over 10 U.S. issued and pending patents and over 70 foreign issued and pending patents related to our stem cell technologies
for use in treating disease and injury. We own over 15 U.S. issued and pending patents and over 70 foreign issued and pending patents
related to our small molecule compounds.
We believe our technology, in combination with our expertise, and
established collaborations with major research institutions, could facilitate the development and commercialization of products
for use in the treatment of a wide array of nervous system disorders including neurodegenerative conditions and regenerative repair
of acute and chronic disease.
Clinical Development Program Review
We have devoted the majority of our efforts and financial resources
to the pre-clinical and clinical development of our small molecule compounds and our stem cell therapeutics. Below is a description
of our most advanced clinical programs, their intended indication and current stage of development.
Clinical Pipeline
Clinical Pipeline Summary
NSI-566 Phase 1 safety trial for the treatment of motor deficits
in stroke has been completed. The database has been locked and we are undergoing full data analysis. The topline results warrant
further studies with larger cohorts to demonstrate safety and efficacy, compared to a randomized control arm. The company has initiated
a Phase 2 trial in China. The Company is also actively planning for a Phase 2/3 efficacy trial in the US.
-
In August 2018, we initiated a Phase 2 trial in China. This trial
will enroll ischemic stroke patients with chronic partial paralysis with moderate to severe motor dysfunction, with the same key
inclusion/exclusion criteria as the Phase 1 trial. All operations will occur at BaYi Brain Hospital, the site of Phase 1 study,
and all follow-up assessments will be conducted by blinded, independent neurologists at Beijing Rehabilitation Hospital.
-
In June 2018, we presented an abstract at the annual International
Society of Stem Cell Research (ISSCR). The abstract released some key findings from our Phase 1 chronic stroke study in China,
namely that NSI-566 treatment of 9 chronically hemiparetic stroke patients resulted in statistically significant improvement from
baseline of motor functioning and clinical status.
-
In March 2016, we completed dosing the final planned cohort, for
a total of nine subjects. Subjects are currently being monitored through their 24-month observational follow-up period. The trial
is being conducted by Suzhou Neuralstem, a wholly owned subsidiary of Neuralstem in China.
NSI-566 Phase 1 and 2 safety trials for the treatment of Amyotrophic
Lateral Sclerosis (ALS): Analysis of combined Phase 1 and 2 data compared to matched historical datasets indicate preliminary evidence
of clinical benefit of stabilizing function in the stem-cell treated patients. We intend to meet with FDA to discuss potential
study designs for an efficacy trial.
|
|
·
|
On May 3, 2018, we announced the results from a study published in the Annals of Clinical and Translational
Neurology in a manuscript entitled “Long-term Phase 1/2 Intraspinal Stem Cell Transplantation Outcomes in Amyotrophic Lateral
Sclerosis” that support the potential of transplanted human spinal cord-derived neural stem cells (HSSC) to stabilize functioning
of ALS patients.
|
NSI-566 Phase 1 safety trial for the treatment of chronic Spinal
Cord Injury (cSCI): The first cohort of 4 subjects (thoracic injury) tolerated the stem cell treatment well and showed early evidence
of benefit; the study has progressed to the second cohort of 4 subjects (cervical injury), which has enrolled 1 patient so far.
-
In June 2018, the study investigators published the results of
the first cohort in the journal
Cell Stem Cell
. The results support the potential of transplanted NSI-566 to benefit patients
with cSCI. At 18 months to 27 months after surgery, the analysis of motor and sensory function and electrophysiology showed improvement
in three of the four patients after NSI-566 transplantation. There was no evidence of serious adverse events, suggesting the procedure
is well-tolerated.
-
In January 2016, we reported on the interim status of the Phase
1 safety data on all four subjects with stable thoracic spinal cord injuries; the stem cell treatment demonstrated feasibility
and safety. A self-reported ability to contract some muscles below the level of injury was confirmed via clinical and electrophysiological
follow-up examinations in one of the four subjects treated. All subjects will be followed for five years. This study is being conducted
with support from the University of California, San Diego (UCSD) School of Medicine.
NSI-189 Phase 2 randomized, placebo-controlled, double-blind clinical
trial for the treatment of MDD: The results point to the potential utility as an augmentation therapy to current antidepressants
(SSRIs) by improving cognition, outlook, and energy that may complement SSRIs. The Company is seeking the advice and financial
support of a partner to determine the best way forward for the MDD program.
|
|
·
|
In July 2017, the company announced, top-line results from its exploratory Phase 2 clinical trial examining the efficacy
of NSI-189 at 40 mg QD and 40 mg BID compared to placebo for the treatment of MDD. The study, which utilized the two-staged sequential
parallel comparison design (SPCD), did not meet its primary efficacy endpoint of a statistically significant reduction in depression
symptoms on the MADRS. However, the 40 mg QD dose was directionally positive on the MADRS. Of secondary efficacy endpoints analyzed
so far, the patient-rated SDQ achieved statistical significance (p=0.044) with NSI-189 40 mg QD compared to placebo in the overall
SPCD analysis. Results were also directionally positive on the Hamilton Depression Rating Scale (HAM-D17) at both doses. Both the
40 mg QD and 40 mg BID doses were well-tolerated with no serious adverse events reported.
|
|
|
·
|
The clinical trial was initiated in May 2016 and the last subject completed the study in May 2017. 220 subjects were randomized
for a 12-week interventional study with NSI-189 or placebo. The study was conducted under the direction of Principal Investigator
(PI) Maurizio Fava, MD, Executive Vice Chair, Department of Psychiatry and Executive Director, Clinical Trials Network and Institute,
Massachusetts General Hospital.
|
Pre-Clinical Development Pipeline
Our preclinical research on NSI-189 is focused on identifying its
mechanism of action and investigating its potential utility as a neuroregenerative drug that can prevent or reverse various types
of central and peripheral nerve degeneration and that may have significant cognitive benefit in diseases that impact memory and
cognition. Recent preclinical data support the potential benefits of NSI-189 in other indications beyond MDD.
|
|
·
|
Since 2016, we have been collaborating with the laboratory of Dr. Baudry at Western University
of Health Sciences, California, and others to obtain proof-of-principle data for NSI-189 in reversing cognitive and neurological
deficits in animal models of Angelman Syndrome, an inherited rare disease with known genetic defect that results in mental developmental
arrest in early childhood. Positive results could position NSI-189 for a Phase 2a clinical trial for adult patients with Angelman
Syndrome.
|
|
|
·
|
Under a Phase 2 Small Business Innovation Research (“SBIR”) grant from NIH/NINDS, we
are collaborating with the laboratory of Drs. Calcutt and Jolivalt at UCSD to obtain the proof-of-principle data for NSI-189 in
preventing/reversing peripheral/central neuropathy due to diabetes in animal models. Positive results could position NSI-189 for
a Phase 2a clinical trial for diabetic neuropathy.
|
|
|
·
|
We are testing NSI-189 in animal models of Alzheimer’s disease at the laboratory of Dr. Jolivalt
at UCSD.
|
|
|
·
|
Therapeutic potential of NSI-189 on cognition has also been tested in an animal model of radiation-induced
brain injury and subsequent cognitive impairment. This study was conducted at the laboratory of Dr. Limoli at University of California
Irvine. The data, published in the journal
Radiation Research
, demonstrate that NSI-189 mitigates the cognitive damage done
by cranial radiotherapy to rats.
|
Our preclinical studies with NSI-566 have served to provide a foundation
for our ongoing clinical trials by demonstrating performance and efficacy of this cell line in animal models for ALS, spinal cord
injury, and ischemic stroke, and demonstrated safety in large animals. Additional studies involving NSI-566 are directed at identifying
new therapeutic indications.
|
|
·
|
We have been collaborating with the laboratory of Dr. Bullock at the University of Miami to obtain
proof-of-principle data for NSI-566 in reversing motor deficits due to severe/penetrating brain injury in animal models. In March
2017, interim preclinical data were published in
Journal of Neurotrauma
, which showed robust engraftment and long-term survival
of NSI-566 post transplantation in a rat model of penetrating ballistic-like brain injury (PBBI). On June 11, 2018, we received
a $150,000 Department of Defense contract to support the development of NSI-566 human neural stem cell line as a candidate therapeutic
for severe Traumatic Brain Injury (TBI).
|
In addition to NSI-566 we have developed an inventory of over
300
unique stem cell lines.
These stem cell lines include cortex, hippocampus, midbrain, hindbrain, cerebellum, and spinal cord.
We believe these lines possess unique properties and represent candidates for both transplantation-based strategies to treat disease
and for screening of compound libraries to discover novel drug therapies.
|
|
·
|
One cell line we have been developing is NSI-532.IGF for Alzheimer’s disease (AD). This cell
line is a fetal cortex-derived neural stem cell line genetically engineered to overexpress human insulin-like growth factor 1 (IGF-1),
which is well-known for its neurogenic and neuroprotective properties. This work is being conducted at the laboratory of Dr. Feldman
at the University of Michigan to obtain proof-of-principle data for NSI-566 in slowing/reversing neurodegeneration in animal models
of AD. In January 2016, preliminary data were published in
Stem Cells Translational Medicine
, which showed a promise as
a possible disease-modifying Alzheimer's intervention.
|
Our Technologies
Small Molecule Pharmaceutical Compounds.
Utilizing our proprietary stem cell-based
screening capability, we have discovered and patented a series of small molecule compounds. We believe our low molecular weight
organic compounds can efficiently cross the blood/brain barrier. In mice, research indicated that the small molecule compounds
both stimulate neurogenesis of the hippocampus and increase its volume. We believe the small molecule compounds may promote synaptogenesis
and neurogenesis in the human hippocampus thereby providing therapeutic benefits in indications such as MDD and may also provide
clinical benefit in indications such as Angelman Syndrome, Diabetic Neuropathy, Cognition, Stroke and Radiation Induced Cognitive
Deficit.
Our portfolio of small molecule compounds which includes NSI-189
are covered by 10 U.S. exclusively owned issued and pending patents and over 60 exclusively owned foreign issued and pending patents.
Stem Cells.
Our
stem cell-based technology has both therapeutic and screening characteristics.
From
a therapeutic perspective, our stem cell-based technology enables the isolation and large-scale expansion of regionally specific,
human neural stem cells from all areas of the developing human brain and spinal cord thus enabling the generation of physiologically
relevant human neurons of different types. We believe that our stem cell technology will enable the replacement or supplementation
of malfunctioning or dead cells thereby creating a neurotrophic environment that offers protection to neural tissue as a way to
treat disease and injury. Many significant and currently untreatable human diseases arise from the loss or malfunction of specific
cell types in the body. Our focus is the development of effective methods to generate replacement cells from neural stem cells.
We believe that creating a neurotrophic environment by replacing damaged, malfunctioning or dead neural cells with fully functional
ones may be a useful therapeutic strategy in treating many diseases and conditions of the central nervous system.
Our Proprietary and Novel Screening
Platform
Our
human neural stem
cell lines form the foundation for functional cell-based assays used to screen for small molecule compounds that can impact biologically
relevant outcomes such as neurogenesis, synapse formation, and protection against toxic insults.
We
have developed over 300 unique stem cell lines representing multiple different regions of the developing brain and spinal cord
at multiple different time points in development, enabling the generation of physiologically relevant human neural cells for screening,
target validation, and mechanism-of-action studies. This platform provides us with a unique and powerful tool to identify new chemical
entities to treat a broad range of nervous system conditions. NSI-189 was discovered using our stem cell-based screening platform.
Intellectual Property
We have developed and maintain what we believe is a strong portfolio
of patents and patent applications that form the basis for our research and development efforts. We own or exclusively license
over 10 U.S. issued and pending patents and over 70 foreign issued and pending patents related to our stem cell technologies for
use in treating disease and injury. We own over 10 U.S. issued and pending patents and over 60 foreign issued and pending patents
related to our small molecule compounds. Our issued patents have expiration dates ranging from 2017 through 2035. Two of our original
patents covering methods and composition of matter associated with our stem cell technologies expired in 2016. In our opinion,
the expiration of these patents is not material to our intellectual property.
Operating Strategy
We generally employ an outsourcing strategy
where we outsource our preclinical and clinical development activities to contract research organizations and academic partners.
Manufacturing of our small molecule portfolio is also outsourced to organizations with approved facilities and manufacturing practices.
Manufacturing of our stem cells is proprietary, and we operate a closed, in-house system to ensure the protection of all critical
know-how associated with the technology. All non-critical corporate functions are outsourced as well. This model allows us to better
manage cash on hand and minimize non-vital expenditures. It also allows for us to operate with relatively fewer employees and lower
fixed costs than that required by other companies conducting similar business.
Employees
As of October 26, 2018, we had five (5) full-time employees. Of
these full-time employees, four (4) work on research and development and clinical operations and one (1) works in administration.
We also use the services of numerous outside consultants in business and scientific matters.
Our Corporate Information
We were incorporated in Delaware in 2001. Our principal executive offices are located
at 20271 Goldenrod Lane, Germantown, Maryland 20876, and our telephone number is (301) 366-4841. Our website is located at www.neuralstem.com.
We have not incorporated by reference into this prospectus supplement the information
in, or that can be accessed through, our website and you should not consider it to be a part of this prospectus supplement.
THE OFFERING
|
Issuer
|
|
Neuralstem, Inc.
|
|
|
|
|
|
Common stock offered by us
|
|
3,000,000 shares of common stock.
|
|
|
|
|
|
Offering price
|
|
$0.70 per share of common stock.
|
|
|
|
|
|
Common stock to be outstanding after this offering
|
|
18,160,014 shares.
|
|
|
|
|
|
Concurrent private placement of Warrants
|
|
We are offering 3,000,000 shares of our common stock in this offering at a price of $0.70 per share. In a
concurrent private placement, we are also issuing to investors Warrants to purchase an additional 3,000,000 shares of our common
stock. Each Warrant will be exercisable for one share of our common stock at an exercise price of $0.75 per share. Each Warrant
shall be exercisable six months after the date of issuance and have a term of exercise equal to five years from the initial exercise
date. The Warrants and the Warrant Shares are not being registered under the Securities Act and are being offered pursuant to an
exemption provided in Section 4(a)(2) of the Securities Act and Rule 506(b) promulgated thereunder. The Warrants
are not and will not be listed for trading on any national securities exchange. Each purchaser will be an “accredited investor”
as such term is defined in Rule 501(a) under the Securities Act.
|
|
|
|
|
|
Use of Proceeds
|
|
We intend to use the net proceeds received from this offering for pre-clinical and clinical activities, working capital and general corporate purposes. Please see “Use of Proceeds” on page S-11.
|
|
Risk Factors
|
|
Investing in our securities involves a high degree
of risk. See “
Risk Factors
” beginning on page S-7 of this prospectus supplement and page 3 of
the accompanying prospectus, as well as the risk factors sections of any documents incorporated by reference into this
prospectus supplement.
|
|
|
|
|
|
Market for our Common Stock
|
|
Our common stock is listed and traded on Nasdaq Capital Market under the symbol “CUR”
|
The number of shares of our common stock to be outstanding immediately
after this offering is based on 15,160,014 shares of our common stock outstanding as of June 30, 2018 and excludes:
|
|
·
|
182,266 shares issued since June 30, 2018;
|
|
|
·
|
3,887,387 shares underlying outstanding Series A 4.5% Convertible Preferred Stock;
|
|
|
·
|
1,832,502 shares underlying outstanding options issued pursuant to our equity compensation and
inducement plans having a weighted average exercise price of $10.37 per share;
|
|
|
·
|
3,897,374 shares of our common stock issuable upon exercise of outstanding warrants having a weighted
average exercise price of $9.14 per share;
|
|
|
·
|
56,281 shares of our common stock reserved for issuance upon the vesting and termination of certain
transfer restrictions with regard to restricted stock units;
|
|
|
·
|
311,699 shares of our common stock reserved for issuance pursuant to future grants and/or award
under our equity compensation and inducement plans; and
|
|
|
·
|
3,00,000 shares of common stock reserved for issuance upon exercise of the warrants offered to the investors
in the concurrent private placement having an exercise price of $0.75 per share; and
|
|
|
·
|
180,000 shares of common stock reserved for issuance upon exercise of the warrants to be issued as compensation
to the placement agent in this offering, having an exercise price of $0.875 per share.
|
Except as otherwise indicated herein, all information in this prospectus
supplement, including the number of shares that will be outstanding after this offering, does not assume or give effect to the
conversion of Preferred Shares or exercise of options or warrants outstanding as of June 30, 2018 or to the exercise of the Warrants
offered in the concurrent private placement or to the Placement Agent Warrants.
RISK FACTORS
Investing in our securities involves a high degree of risk. Before
making an investment decision, you should carefully consider the risks described below, together with all of the other information
included in this prospectus supplement, the accompanying prospectus, and the information incorporated by reference herein and therein.
For a discussion of additional risks associated with our business,
our intellectual property, government regulation and approval of our product candidates, our industry and an investment in our
common stock, see the section entitled “Risk Factors” in our most Annual Report on Form 10-K, for the year ended December
31, 2017, and any other subsequently filed document that is also incorporated or deemed to be incorporated by reference in this
prospectus supplement.
If any of the risks described below, or those incorporated by
reference into this prospectus supplement actually occur, our business, financial condition or results of operations could suffer.
In that case, the trading price of our common stock may decline and you may lose all or part of your investment. The risks and
uncertainties we have described are not the only ones we face. Additional risks and uncertainties not presently known to us or
that we currently deem immaterial may also affect our business, financial condition and results of operations. Certain statements
below are forward-looking statements. See the information included under the heading “Note Regarding Forward-Looking Statements.”
Our management will have broad discretion over the use of
the net proceeds from this offering, you may not agree with how we use the proceeds and the proceeds may not be invested successfully.
Our management will have broad discretion as to the use of the net proceeds from this offering and could use
them for purposes other than those contemplated currently and described under “Use of Proceeds” on page S-11. Accordingly,
you will be relying on the judgment of our management with regard to the use of these net proceeds, and you will not have the opportunity,
as part of your investment decision, to assess whether the proceeds are being used appropriately. It is possible that, pending
their use, we may invest the net proceeds in a way that does not yield a favorable, or any, return for our company.
There may be future sales or other dilution of our equity,
which may adversely affect the market price of our common stock.
We are generally not restricted from issuing additional common stock,
including any securities that are convertible into or exchangeable for, or that represent the right to receive, common stock. The
market price of our common stock could decline as a result of sales of common stock or securities that are convertible into or
exchangeable for, or that represent the right to receive, common stock after this offering or the perception that such sales could
occur.
You will experience immediate and substantial dilution in
the net tangible book value per share of our common stock.
The public offering price of our common stock and accompanying warrant
being offered is substantially higher than the net tangible book value per share of our common stock outstanding prior to this
offering. Therefore, if you purchase our common stock and warrants in this offering, you will incur an immediate substantial dilution
of $0.30 in net tangible book value per share from the price you paid, based on our financial statements as of June 30, 2018. If
the warrants offered hereby or outstanding options or warrants to purchase our common stock are exercised, you will experience
additional dilution. For a further description of the dilution that you will experience immediately after this offering, see “Dilution.”
As a result of this offering, 3,996,154
warrants with anti-dilution price protection provisions will have their exercise prices reduced to the offering price, or in some
cases, below the offering price.
As a result of this offering, 3,996,154
warrants with anti-dilution price protection provisions will have their exercise prices reduced. These warrants include (i) 1,538,462
warrants issued in our May 2016 registered offering, (ii) 207,692 warrants issued in our May 2016 private placement, and (iii)
2,250,000 warrants issued in our August 2017 registered offering. Each of these outstanding warrants will have their exercise prices
reduced to at least the offering price of the securities sold hereunder. The warrants issued in our August 2017 offering may be
reduced to the quotient of the sum of the three lowest volume weighted average prices of the common stock during the five trading
day period immediately following the public announcement of the dilutive issuance (October 25, 2018) divided by three.
NOTE REGARDING FORWARD-LOOKING STATEMENTS
This prospectus supplement, the accompanying prospectus and the
other documents we have filed with the SEC that are incorporated herein by reference contain forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties, as well as assumptions
that, if they never materialize or prove incorrect, could cause our results to differ materially from those expressed or implied
by such forward-looking statements. All statements other than statements of historical fact are statements that could be deemed
forward-looking statements, including any projections of financing needs, revenue, expenses, earnings or losses from operations,
or other financial items, any statements of the plans, strategies and objectives of management for future operations, any statements
concerning product research, development and commercialization plans and timelines, any statements regarding safety and efficacy
of product candidates, any statements of expectation or belief and any statements of assumptions underlying any of the foregoing.
In addition, forward-looking statements may contain the words “believe,” “anticipate,” “expect,”
“estimate,” “intend,” “plan,” “project,” “will be,” “will continue,”
“will result,” “seek,” “could,” “may,” “might,” or any variations of
such words or other words with similar meanings. All forward-looking statements attributable to us or to persons acting on our
behalf are expressly qualified in their entirety by the cautionary statements and risk factors set forth in the “Risk Factors”
section and elsewhere in this prospectus supplement, in the accompanying prospectus and in our Annual Report on Form 10-K for the
year ended December 31, 2017 and any subsequent Quarterly Reports on Form 10-Q filed with the SEC.
Given these uncertainties, you should not place undue reliance on
these forward-looking statements. You should read this prospectus supplement, the accompanying prospectus and the documents incorporated
by reference in this prospectus supplement and the accompanying prospectus with the understanding that our actual future results
may be materially different from what we expect. Except as required by law, we do not undertake any obligation to update or revise
any forward-looking statements contained in this prospectus supplement, the accompanying prospectus or such other documents, whether
as a result of new information, future events or otherwise.
USE OF PROCEEDS
We estimate that the net proceeds from this offering, after payment of placement agent
fees and estimated offering expenses and other fees payable by us, will be approximately $1.9 million.
Except as otherwise described in any free writing prospectus that we may authorize to
be furnished to you, we currently intend to use the net proceeds from this offering to further our clinical and preclinical programs
and for working capital and general corporate purposes.
We have not determined the amounts we plan to spend on any of the areas listed above
or the timing of these expenditures. As a result, our management will have broad discretion to allocate the net proceeds from this
offering. Pending application of the net proceeds as described above, we expect to invest the net proceeds in short-term, interest-bearing,
investment-grade securities.
DIVIDEND POLICY
Our business requires significant funding. We currently plan to invest all available
funds and any future earnings in our business and do not anticipate paying any cash dividends on our common stock in the foreseeable
future. We currently are prohibited by the terms of our outstanding indebtedness from paying dividends on our common stock, except
with the prior consent of our lenders.
DILUTION
Our net tangible book value as of June 30, 2018, was approximately
$5.4 million, or $0.35 per share of our common stock. Net tangible book value per share of our common stock is determined by dividing
total tangible assets (less total tangible liabilities) by the aggregate number of shares of our common stock outstanding as of
June 30, 2018. Dilution in net tangible book value per share represents the difference between the amount per share paid by purchasers
of shares of common stock and accompanying warrants in this public offering and the net tangible book value per share of our common
stock immediately after this offering.
After giving effect to the sale of 3,000,000 shares of common stock in this offering at a price of $0.70 per
share and warrant, and after deducting estimated placement agent fees and other estimated offering expenses paid or payable by
us, our as adjusted net tangible book value as of June 30, 2018 would have been approximately $7.2 million, or approximately $0.40
per share. This represents an immediate increase in net tangible book value of $0.05 per share to our existing stockholders and
immediate dilution in net tangible book value of $0.30 per share to purchasers in this offering. The following table illustrates
this calculation on a per share basis:
|
Offering price per share in this offering
|
|
|
|
|
|
$
|
0.70
|
|
|
Net tangible book value per share as of June 30, 2018
|
|
$
|
0.35
|
|
|
|
|
|
|
Increase in as adjusted net tangible book value per share attributable to purchasers in this offering
|
|
$
|
0.05
|
|
|
|
|
|
|
As adjusted net tangible book value per share immediately after this offering
|
|
|
0
|
|
|
|
0.40
|
|
|
Dilution per share to purchasers in this offering
|
|
|
0
|
|
|
$
|
0.30
|
|
The number of shares of our common stock to be outstanding immediately after this offering
is based on 15,160,014 shares of our common stock outstanding as of June 30, 2018 and excludes:
• 182,266 shares issued
since June 30, 2018;
• 3,887,387 shares
underlying outstanding Series A 4.5% Convertible Preferred Stock;
• 1,832,502 shares
underlying outstanding options issued pursuant to our equity compensation and inducement plans having a weighted average exercise
price of $10.37 per share;
• 3,897,374 shares
of our common stock issuable upon exercise of outstanding warrants having a weighted average exercise price of $9.14 per share;
• 56,281 shares of
our common stock reserved for issuance upon the vesting and termination of certain transfer restrictions with regard to restricted
stock units;
• 311,699 shares of
our common stock reserved for issuance pursuant to future grants and/or award under our equity compensation and inducement plans;
and
• 3,180,000 shares
of common stock reserved for issuance upon exercise of the warrants offered hereby
The above illustration of dilution per share to investors participating in this offering
assumes no exercise of options or warrants to purchase shares of our common stock, including the Warrants to be issued to the purchasers
in this offering in the concurrent private placement or the Placement Agent Warrants (see “Private Placement of Warrants”
for more information). The exercise of any such securities will increase dilution to purchasers in this offering.
Because there is no minimum offering amount required as a condition to the closing of
this offering, the dilution per share to new investors may be more than that indicated above in the event that the actual number
of shares sold, if any, is less than the maximum number of shares of common stock we are offering.
PRIVATE PLACEMENT OF WARRANTS
In a concurrent private placement, we are issuing to each of the investors in this offering Warrants to purchase
additional shares of our common stock. The aggregate number of Warrant Shares exercisable pursuant to the Warrants is 3,000,000.
The Warrants will be exercisable at an exercise price of $0.75 per share. The exercise price and number of Warrant Shares issuable
upon the exercise of the Warrants will be subject to adjustment in the event of any stock dividend and split, reverse stock split,
recapitalization, reorganization or similar transaction, as described in the Warrants.
Each Warrant shall be exercisable six months after the date of issuance and have a term of exercise equal to
five years from the initial exercise date. A holder of Warrants will have the right to exercise the Warrants on a “cashless”
basis in certain circumstances as described in the Warrants, including, among others, while there is no effective registration
statement registering the Warrant Shares issuable upon exercise of the Warrants. Subject to limited exceptions, a holder of Warrants
will not have the right to exercise any portion of its Warrants if the holder, together with its affiliates, would beneficially
own in excess of 4.99% of the number of shares of our common stock outstanding immediately after giving effect to such exercise,
provided that the holder may increase or decrease the beneficial ownership limitation up to 9.99%, provided, further, that any
increase in the beneficial ownership limitation shall not be effective until 61 days following notice of such change to the Company.
The Warrants and the Warrant Shares are not being registered under
the Securities Act pursuant to the registration statement of which this prospectus supplement and the accompanying base prospectus
form a part and are not being offered pursuant to this prospectus supplement and the accompanying base prospectus. The Warrants
and the Warrant Shares are being offered pursuant to the exemption provided in Section 4(a)(2) of the Securities Act
and Rule 506(b) promulgated thereunder. All purchasers are required to be “accredited investors” as such
term is defined in Rule 501(a) under the Securities Act.
PLAN OF DISTRIBUTION
Pursuant to an engagement letter agreement dated
October 25, 2018, we have engaged H.C. Wainwright & Co., LLC (“Wainwright” or the “placement
agent”) to act as our exclusive placement agent in connection with this offering of our shares of common stock pursuant
to this prospectus supplement and accompanying prospectus. Under the terms of the engagement letter, the placement agent has
agreed to be our exclusive placement agent, on a reasonable best efforts basis, in connection with the issuance and sale by
us of our shares of common stock in this takedown from our shelf registration statement. The terms of this offering were
subject to market conditions and negotiations between us, the placement agent and prospective investors. The engagement
letter does not give rise to any commitment by the placement agent to purchase any of our shares of common stock, and the
placement agent will have no authority to bind us by virtue of the engagement letter. Further, the placement agent does not
guarantee that it will be able to raise new capital in any prospective offering. The placement agent may engage sub-agents or
selected dealers to assist with this offering.
The placement agent proposes to arrange for the sale of the shares
we are offering pursuant to this prospectus supplement and accompanying prospectus to one or more investors through securities
purchase agreements directly between the purchasers and us.
We expect to deliver the shares of our common stock being offered pursuant to this prospectus supplement
on or about October 29, 2018, subject to customary closing conditions.
We have agreed to pay the placement agent a total cash fee equal
to 7.0% of the gross proceeds of this offering. We will also pay the placement agent $25,000 for non-accountable expenses and an
expense allowance of $35,000 for legal fees and other out-of-pocket expenses. We estimate the total expenses payable by us for
this offering will be approximately $0.2 million, which amount includes the placement agent’s fees and reimbursable expenses.
In addition, we have agreed to issue to the placement agent Placement Agent Warrants to purchase up to 6.0% of the aggregate number
of shares of common stock sold in this offering (180,000 shares). The Placement Agent Warrants will have substantially the same
terms as the Warrants issued to the investors in the concurrent private placement, except that the Placement Agent Warrants will
have an exercise price equal to $0.875, or 125% of the offering price per share in this offering and such Placement Agent Warrants
will be exercisable for five years from the effective date of this offering. Pursuant to FINRA Rule 5110(g), the Placement
Agent Warrants and any shares issued upon exercise of the Placement Agent Warrants shall not be sold, transferred, assigned, pledged,
or hypothecated, or be the subject of any hedging, short sale, derivative, put or call transaction that would result in the effective
economic disposition of the securities by any person for a period of 180 days immediately following the date of effectiveness or
commencement of sales of this offering, except the transfer of any security: (i) by operation of law or by reason of our reorganization;
(ii) to any FINRA member firm participating in this offering and the officers or partners thereof, if all securities so transferred
remain subject to the lock-up restriction set forth above for the remainder of the time period; (iii) if the aggregate amount
of our securities held by the placement agent or related persons do not exceed 1% of the securities being offered; (iv) that
is beneficially owned on a pro-rata basis by all equity owners of an investment fund, provided that no participating member manages
or otherwise directs investments by the fund and the participating members in the aggregate do not own more than 10% of the equity
in the fund; or (v) the exercise or conversion of any security, if all securities remain subject to the lock-up restriction
set forth above for the remainder of the time period.
We have agreed to indemnify the placement agent
and specified other persons against certain liabilities relating to or arising out of the placement agent’s activities under
the placement agency agreement and to contribute to payments that the placement agent may be required to make in respect of such
liabilities.
The placement agent may be deemed to be an
underwriter within the meaning of Section 2(a)(11) of the Securities Act, and any commissions received by it and any profit
realized on the resale of the securities sold by it while acting as principal might be deemed to be underwriting discounts or commissions
under the Securities Act. As an underwriter, the placement agent would be required to comply with the requirements of the Securities
Act and the Exchange Act, including, without limitation, Rule 415(a)(4) under the Securities Act and Rule 10b-5
and Regulation M under the Exchange Act. These rules and regulations may limit the timing of purchases and sales of shares
of common stock and warrants by the placement agent acting as principal. Under these rules and regulations, the placement
agent:
·
may not engage in any stabilization activity in connection with our securities; and
·
may not bid for or purchase any of our securities or attempt to induce
any person to purchase any of our securities, other than as permitted under the Exchange Act, until it has completed its participation
in the distribution.
From time to time, the placement agent may provide in the future various advisory, investment
and commercial banking and other services to us in the ordinary course of business, for which they have received and may continue
to receive customary fees and commissions. However, except as disclosed in this prospectus supplement, we have no present arrangements
with the placement agent for any further services.
LEGAL MATTERS
The validity of the issuance of the securities offered hereby will be passed upon for
us by the Silvestre Law Group, P.C., Westlake Village, California. The Silvestre Law Group, P.C. or its affiliates or principals
own 46,156 of our common stock purchase warrants.
EXPERTS
The financial statements incorporated in this prospectus by reference from our Annual
Reports on Form 10-K have been audited by Dixon Hughes Goodman LLP, our current independent registered public accounting firm.
Such financial statements have been so incorporated in reliance upon their authority as experts in accounting and auditing. The
firm does not have an interest in the shares being registered in the registration statement to which this prospectus supplement
forms a part.
WHERE YOU CAN FIND MORE INFORMATION
We are a public company and file annual, quarterly and current reports, proxy statements
and other information with the SEC. You may obtain copies of our public filings, as noted in the paragraph below or by writing
or telephoning us at:
Neuralstem, Inc.
Attn: Investor Relations
20271 Goldenrod Lane
Germantown, Maryland 20876
Phone: (301)-366-4960
Our SEC filings are available to the public over the Internet at the SEC’s website
at
http://www.sec.gov
. You may also read and copy any document we file at the SEC’s Public Reference Room at 100 F
Street, NE, Washington, D.C. 20549. Please call the SEC at 1-800-SEC-0330 for further information on the Public Reference Room.
You can also inspect reports, proxy statements and other information about us at the offices of the National Association of Securities
Dealers, Reports Section, 1735 K Street, N.W., Washington, D.C. 20006. We maintain a website at http://www.neuralstem.com.
Information contained in or accessible through our website does not constitute a part of this prospectus.
This prospectus supplement and the accompanying prospectus are part of a registration
statement on Form S-3 that we filed with the SEC registering the securities that may be offered and sold hereunder. The registration
statement, including exhibits thereto, contains additional relevant information about us and these securities that, as permitted
by the rules and regulations of the SEC, we have not included in this prospectus supplement or the accompanying prospectus.
A copy of the registration statement can be obtained at the address set forth above. You should read the registration statement
for further information about us and these securities.
INCORPORATION OF DOCUMENTS BY REFERENCE
The SEC permits us to “incorporate by reference” the information contained
in documents we file with the SEC, which means that we can disclose important information to you by referring you to those documents
rather than by including them in this prospectus supplement or the accompanying prospectus. Information that is incorporated by
reference is considered to be part of this prospectus supplement, and you should read it with the same care that you read this
prospectus supplement. Later information that we file with the SEC will automatically update and supersede the information that
is either contained, or incorporated by reference, in this prospectus supplement, and will be considered to be a part of this prospectus
supplement from the date those documents are filed.
We incorporate by reference into this prospectus supplement the following documents and
information filed with the SEC:
|
|
·
|
Our Annual Report on Form 10-K filed with the Commission on April 2, 2018, for the year ended December 31, 2017;
|
|
|
·
|
Our Quarterly Reports on Form 10-Q filed with the Commission on May 15, 2018 (for the the three months ended March 31, 2018) and August 13, 2018 (for the three and six months ended June 30, 2018);
|
|
|
·
|
Our Definitive Proxy Statement on Form 14A for our 2018 Annual Meeting of Stockholders, filed with the SEC on April 25, 2018;
|
|
|
·
|
Our Current Reports on Form 8-K filed with the Commission on January 9, 2018, January 24, 2018, March 16, 2018, April 2, 2018, May 15, 2018, June 8, 2018, June 14, 2018, June 14, 2018, July 5, 2018, August 9, 2018, August 15, 2018 and October 29, 2018 (excluding any information furnished in such reports under Item 2.02 and Item 7.01); and
|
|
|
·
|
the description of our common stock and related rights contained in our registration statement on Form 8-A (File No. 001-33672), filed with the Commission on July 1, 2015, including any amendment or report filed for the purpose of updating such description.
|
We also incorporate by reference into this prospectus supplement all additional documents
that we file with the SEC under the terms of Section 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934 that
are made after the date of this prospectus supplement and before the termination of the offering of securities offered by this
prospectus supplement. We are not, however, incorporating, in each case, any documents or information that we are deemed to furnish
and not file in accordance with SEC rules.
You may request a copy of any of the documents incorporated by reference into this prospectus
supplement, at no cost, by writing or telephoning us at the following address: Neuralstem, Inc., Attn: Investor Relations, 20271
Goldenrod Lane, Germantown, Maryland 20876 Phone: 301-366-4960.
Filed Pursuant to Rule 424(b)(2)
Registration No. 333-218608
PROSPECTUS
NEURALSTEM, INC.
$100,000,000
COMMON STOCK
PREFERRED STOCK
WARRANTS
RIGHTS
PURCHASE CONTRACTS
UNITS
This prospectus will allow us to issue,
from time to time at prices and on terms to be determined at or prior to the time of the offering, up to $100,000,000 of any combination
of the securities described in this prospectus, either individually or in units. We may also offer common stock upon conversion
of or exchange for the preferred stock; common stock or preferred stock upon the exercise of warrants, rights or performance of
purchase contracts; or any combination of these securities upon the performance of purchase contracts.
This prospectus describes the general terms
of these securities and the general manner in which these securities will be offered. We will provide you with the specific terms
of any offering in one or more supplements to this prospectus. The prospectus supplements will also describe the specific manner
in which these securities will be offered and may also supplement, update or amend information contained in this document. You
should read this prospectus and any prospectus supplement, as well as any documents incorporated by reference into this prospectus
or any prospectus supplement, carefully before you invest.
Our securities may be sold directly by
us to you, through agents designated from time to time or to or through underwriters or dealers. For additional information on
the methods of sale, you should refer to the section entitled “Plan of Distribution” in this prospectus and in the
applicable prospectus supplement. If any underwriters or agents are involved in the sale of our securities with respect to which
this prospectus is being delivered, the names of such underwriters or agents and any applicable fees, commissions or discounts
and over-allotment options will be set forth in a prospectus supplement. The price to the public of such securities and the net
proceeds that we expect to receive from such sale will also be set forth in a prospectus supplement.
The aggregate market value of our outstanding
co
mmon stock held by non-affiliates was $42,236,000 based on 11,911,877 shares of outstanding
common stock as of May 31, 2017 of which approximately 9,470,044 shares were held by non-affiliates, and based on the last reported
sale price of our common stock as noted above. Pursuant to General Instruction I.B.6 of Form S-3, in no event will we sell securities
pursuant to this prospectus with a value of more than one-third of the aggregate market value of our common stock held by non-affiliates
in any twelve-month period, so long as the aggregate market value of our common stock held by non-affiliates is less than $75,000,000.
In the event that subsequent to the date of this prospectus, the aggregate market value of our outstanding common stock held by
non-affiliates equals or exceeds $75,000,000, then the one-third limitation on sales shall not apply to additional sales made
during the corresponding you in reliance on this prospectus. During the prior twelve ca
lendar months prior to, and including,
the date of this prospectus, we have not sold any securities pursuant to General Instruction I.B.6 of Form S-3.
Our common stock is listed on the NASDAQ
Capital Market under the symbol “CUR” On May 31, 2017, the last reported sale price of our common stock was $4.46
per share. The applicable prospectus supplement will contain information, where applicable, as to any other listing, if any, on
the NASDAQ Capital Market or any securities market or other securities exchange of the securities covered by the prospectus supplement.
Prospective purchasers of our securities are urged to obtain current information as to the market prices of our securities, where
applicable. Our principal executive offices are located at 20271 Goldenrod Lane, Germantown, Maryland 20876, and our telephone
number is (301) 366-4960.
INVESTING IN OUR SECURITIES INVOLVES
RISKS. YOU SHOULD REVIEW CAREFULLY THE RISKS AND UNCERTAINTIES DESCRIBED UNDER THE HEADING “
RISK FACTORS
” ON
PAGE 6 AND CONTAINED IN THE APPLICABLE PROSPECTUS SUPPLEMENT AND ANY RELATED FREE WRITING PROSPECTUS AND UNDER SIMILAR HEADINGS
IN THE OTHER DOCUMENTS THAT ARE INCORPORATED BY REFERENCE INTO THIS PROSPECTUS.
Neither the Securities and Exchange
Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus
is truthful or complete. Any representation to the contrary is a criminal offense.
This prospectus is dated June 26,
2017
Table of Contents
ABOUT THIS PROSPECTUS
Unless the context requires
otherwise or unless otherwise noted, all references in this prospectus or any prospectus supplement to
“our company,”
“we,” “our,” “Neuralstem” and “us” refer to Neuralstem, Inc. and its subsidiaries.
Also, any reference to “common share” or “common stock,” refers to our $0.01 par value common stock. Additionally,
any reference to “Series A Preferred Stock” refers to our Series A 4.5% Convertible Preferred Stock.
This prospectus is a part of a registration
statement that we filed with the Securities and Exchange Commission, or SEC, utilizing a “shelf” registration process.
Under this shelf process, we may sell the securities described in this prospectus in one or more offerings. This prospectus
provides you with a general description of the securities we may offer. Each time we sell securities under this shelf registration,
we will provide a prospectus supplement that will contain specific information about the terms of that offering. We may also
authorize one or more free writing prospectuses to be provided to you that may contain material information relating to these offerings.
The prospectus supplement and any related free writing prospectus that we may authorize to be provided to you may also add, update
or change information contained in this prospectus or in any documents that we have incorporated by reference into this prospectus.
You should read this prospectus, any applicable prospectus supplement and any related free writing prospectus, together with the
information incorporated herein by reference as described under the headings “Where You Can Find More Information”
and “Incorporation by Reference.”
You should rely only on the information
that we have provided or incorporated by reference in this prospectus, any applicable prospectus supplement and any related free
writing prospectus that we may authorize to be provided to you. We have not authorized any dealer, salesman or other person
to give any information or to make any representation other than those contained or incorporated by reference in this prospectus,
any applicable prospectus supplement or any related free writing prospectus that we may authorize to be provided to you.
You must not rely upon any information or representation not contained or incorporated by reference in this prospectus or the accompanying
prospectus supplement. We take no responsibility for, and can provide no assurance as to the reliability of, any other information
that others may give you.
This prospectus and the accompanying supplement
to this prospectus do not constitute an offer to sell or the solicitation of an offer to buy any securities other than the registered
securities to which they relate, nor do this prospectus and the accompanying supplement to this prospectus constitute an offer
to sell or the solicitation of an offer to buy securities in any jurisdiction to any person to whom it is unlawful to make such
offer or solicitation in such jurisdiction. You should not assume that the information contained in this prospectus, any
applicable prospectus supplement or any related free writing prospectus is accurate on any date subsequent to the date set forth
on the front of the document or that any information we have incorporated by reference is correct on any date subsequent to the
date of the document incorporated by reference, even though this prospectus, any applicable prospectus supplement or any related
free writing prospectus is delivered or securities sold on a later date.
FORWARD-LOOKING STATEMENTS
The SEC encourages companies to disclose
forward-looking information so that investors can better understand a company’s future prospects and make informed investment
decisions. This prospectus and the documents we have filed with the SEC that are incorporated herein by reference contain such
“forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995.
Such statements in connection with any
discussion of future operations or financial performance are identified by the use of words such as “may,” “anticipate,”
“estimate,” “expect,” “project,” “intend,” “plan,” “believe,”
and other words and terms of similar meaning. Forward-looking statements include, but are not limited to, statements about: our
business, operations, financial performance and condition, earnings, our prospects, our ability to raise capital to fund our operations
and business plan, the continued listing of our securities on the NASDAQ Capital Market, our ability to protect intellectual property
rights as well as regarding our industry generally. Forward–looking statements are not guarantees of performance. Such statements
are based on management’s expectations and are subject to certain factors, risks and uncertainties that may cause actual
results, outcome of events, timing and performance to differ materially from those expressed or implied by such statements. For
a summary of such factors, please refer to the section entitled “Risk Factors” in this prospectus, as updated and supplemented
by the discussion of risks and uncertainties in our most recent annual report on Form 10-K, as revised or supplemented by our subsequent
quarterly reports on Form 10-Q or our current reports on Form 8-K, as well as any amendments thereto, as filed with the SEC and
which are incorporated herein by reference. The information contained in this document is believed to be current as of the date
of this document. We do not intend to update any of the forward-looking statements after the date of this document to conform these
statements to actual results or to changes in our expectations, except as required by law.
In light of these assumptions, risks and
uncertainties, the results and events discussed in the forward-looking statements contained in this prospectus or in any document
incorporated herein by reference might not occur. Investors are cautioned not to place undue reliance on the forward-looking statements,
which speak only as of the date of this prospectus or the date of the document incorporated by reference in this prospectus. We
are not under any obligation, and we expressly disclaim any obligation, to update or alter any forward-looking statements, whether
as a result of new information, future events or otherwise. All subsequent forward-looking statements attributable to us or to
any person acting on our behalf are expressly qualified in their entirety by the cautionary statements contained or referred to
in this section.
Our Business
Overview
We are focused on the research and development
of nervous system therapies based on our proprietary human neural stem cells and our small molecule compounds with the ultimate
goal of gaining approval from the United States Food and Drug Administration or FDA, and its international counterparts, to market
and commercialize such therapies. We are headquartered in Germantown, Maryland.
Our technology has produced three primary
assets: our NSI-189 small molecule program, our NSI-566 stem cell therapy program and our novel and proprietary chemical entity
screening platform.
Our patented technologies enable the commercial-scale
production of multiple types of central nervous system stem cells, which are under development for the potential treatment of nervous
system diseases and conditions. In addition, this ability to generate human neural stem cell lines provides a platform for chemical
screening and discovery of novel compounds that we believe may be used to stimulate the brain's capacity to regenerate neurons,
thereby potentially treating or reversing pathologies associated with certain nervous system conditions.
We have developed and maintain what we
believe is a strong portfolio of patents and patent applications that form the proprietary base for our research and development
efforts. We own or exclusively license over 20 U.S. issued and pending patents and over 120 foreign issued and pending patents
in the field of regenerative medicine, related to our stem cell technologies as well as our small molecule compounds.
We believe our technology, in combination
with our expertise, and established collaborations with major research institutions, could facilitate the development and commercialization
of products for use in the treatment of a wide array of nervous system disorders including neurodegenerative conditions and regenerative
repair of acute and chronic disease.
Recent Clinical & Business Highlights
|
|
·
|
NSI-189 Phase 2 Major Depressive Disorder (MDD) study results expected 4 months ahead of schedule
in 3Q17. Neuralstem’s Phase 2 clinical study evaluating NSI-189 for the indication of MDD was initiated in May 2016.
The company announced 50% enrollment in September 2016 and last subject enrolled in February 2017. 220 subjects were randomized
for a 12-week interventional study with NSI-189 or placebo. Subjects completing the study are eligible to enroll in a 24-week non-interventional,
observation-only durability study, from which the results are expected in the first half of 2018.
|
|
|
·
|
NSI-189 preclinical data published in the Journal of Cellular Physiology showed oral administration
of NSI-189 in rats with ischemic stroke led to a significant recovery from motor deficit. The improvements were maintained post
cessation of dosing for the additional 12-week observational period. The sustained improvement suggests that NSI-189 initiated
a host brain repair mechanism enabling tissue remodeling of the stroke brain.
|
|
|
·
|
In April 2017, a new cohort (Group B) of four subjects with stable cervical injuries was added
for recruitment to the Phase 1 chronic spinal cord injury (cSCI) human clinical trial evaluating the safety and feasibility of
treatment with NSI-566. The amended protocol was approved by the U.S. Food and Drug Administration and the Institutional
Review Board at the study site, University of California San Diego (UCSD).
|
|
|
·
|
NSI-566 preclinical data in a rat model of penetrating ballistic-like brain injury (PBBI) was published
in the Journal of Neurotrauma. These data showed robust engraftment and long-term survival of NSI-566 post transplantation.
|
|
|
·
|
In January 2017, the Company executed a 1-for-13 reverse stock split of the Company’s common
stock. The reverse stock split enabled Neuralstem to regain compliance with the $1.00 minimum bid price condition and thereby fulfill
all of the NASDAQ Capital Market continued listing requirements.
|
|
|
·
|
In March and April 2017, we received approximately $2,750,000 upon the exercise of 846,156 common
stock purchase warrants issued in our May 2016 registered offering at an exercise price of $3.25 per share. We expect that our
existing cash and cash equivalents will be sufficient to enable us to fund our anticipated level of operations based on our current
operating plans, into the third quarter of 2018.
|
Clinical Development Program Review
We have devoted substantially all of our
efforts and financial resources to the pre-clinical and clinical development of our small molecule compounds and our stem cell
therapeutics. Below is a description of our most advanced clinical programs, their intended indication and current stage of development.
Clinical Pipeline:
Pipeline Summary
NSI-189 Phase 2 randomized, placebo-controlled,
double-blind clinical trial for the treatment of MDD
-
In February 2017, the company announced the last subject enrolled and results expected
four months ahead of schedule in 3Q17. The first subject enrolled in May 2016 and 50% enrollment was achieved in September 2016.
The Phase 2 trial randomized 220 subjects for a 12-week interventional study with NSI-189 across three arms (40mg QD, 40mg BID
or placebo), at 12 select trial sites, all in the U.S. Eligible subjects are given the opportunity to enroll in a separate 24-week
observational study to assess durability of effect defined as the time until the start of a new antidepressant treatment (ADT).
Both the interventional and observational studies are being conducted and under the direction of study Principal Investigator (PI)
Maurizio Fava, MD, Executive Vice Chair, Department of Psychiatry and Executive Director, Clinical Trials Network and Institute,
Massachusetts General Hospital.
NSI-566 Phase 1 and 2 safety trials for
the treatment of Amyotrophic Lateral Sclerosis (ALS)
-
In September 2015, nine-month Phase 2 and combined Phase 1 and Phase 2 data from
our ALS trials were presented at the American Neurological Association Meeting by Principal Investigator Eva Feldman, MD, PhD,
Director of the A. Alfred Taubman Medical Research Institute and Director of Research of the ALS Clinic at the University of Michigan
Health. The data showed that the intraspinal transplantation of the cells was safe and well tolerated. Subjects from both the Phase
1 and Phase 2 continue to be monitored for long-term follow-up evaluations.
NSI-566 Phase 1 safety trial for the treatment
of motor deficits in stroke
-
In March 2016, we completed dosing the final planned cohort, for a total of nine
subjects. Subjects are currently being monitored through their 24-month observational follow-up period. The trial is being conducted
by Suzhou Neuralstem, a wholly owned subsidiary of Neuralstem in China.
NSI-566 Phase 1 safety trial for the treatment
of chronic Spinal Cord Injury (cSCI)
-
In April 2017, the company announced that it had received FDA approval to recruit
a new cohort (Group B) of four subjects with stable AISA-A complete, quadriplegic, cervical injuries to the ongoing Phase 1 human
clinical trial evaluating the safety and feasibility of using NSI-566 spinal cord-derived neural stem cells to repair chronic cSCI.
In January 2016, we reported on the interim status of the Phase 1 safety data on all four subjects with stable thoracic spinal
cord injuries; the stem cell treatment demonstrated feasibility and safety. A self-reported ability to contract some muscles below
the level of injury was confirmed via clinical and electrophysiological follow-up examinations in one of the four subjects treated.
All subjects will be followed for five years. This study is being conducted with support from the University of California, San
Diego (UCSD) School of Medicine.
Pre-Clinical Development Pipeline
Our preclinical research on NSI-189 is
focused on identifying its mechanism of action and investigating its potential utility as a broad neuroregenerative drug that can
prevent or reverse various types of central and peripheral nerve degeneration and that may have significant cognitive benefit in
diseases that impact memory and cognition. Recent preclinical data support the potential benefits of NSI-189 in other indications
beyond MDD.
Our preclinical studies with NSI-566 have
served to provide a solid foundation for our ongoing clinical trials by demonstrating performance and efficacy of this cell line
in animal models for ALS, spinal cord injury, and ischemic stroke, and demonstrated safety in large animals. Additional studies
involving NSI-566 are directed at identifying new therapeutic indications.
In addition to NSI-566 we have developed
an inventory of over
300 unique stem cell lines.
These stem cell lines include cortex,
hippocampus, midbrain, hindbrain, cerebellum, and spinal cord. We believe these lines possess unique properties and represent candidates
for both transplantation-based strategies to treat disease and for screening of compound libraries to discover novel drug therapies.
Our Technologies
Our technology has produced three primary
assets: our NSI-189 small molecule program, our NSI-566 stem cell therapy program and our novel and proprietary chemical entity
screening platform.
Small Molecule Pharmaceutical Compounds.
Utilizing our
proprietary stem cell-based screening capability, we have discovered and patented a series of small molecule compounds. We believe
our low molecular weight organic compounds can efficiently cross the blood/brain barrier. In mice, research indicated that the
small molecule compounds both stimulate neurogenesis of the hippocampus and increase its volume. We believe the small molecule
compounds may promote synaptogenesis and neurogenesis in the human hippocampus in indications such as MDD.
Our portfolio of small molecule compounds
which includes NSI-189 are covered by 7 patent families related to small molecule pharmaceuticals, including granted patents in
the U.S. covering these pharmaceuticals as compositions of matter, granted patents in the U.S. and abroad covering methods of manufacture
and methods of identifying additional candidates, and granted patents and pending applications in the U.S. and abroad covering
indications for which these pharmaceuticals are useful.
Stem Cells.
Therapeutic
Characteristics
From
a therapeutic perspective, our stem cell based technology enables the isolation and large-scale expansion of regionally specific,
human neural stem cells from all areas of the developing human brain and spinal cord thus enabling the generation of physiologically
relevant human neurons of different types. We believe that our stem cell technology will enable the replacement of malfunctioning
or dead cells or the protection of neurons as a way to treat disease and injury. Many significant and currently untreatable human
diseases arise from the loss or malfunction of specific cell types in the body. Our focus is the development of effective methods
to generate replacement cells from neural stem cells. We believe that replacing damaged, malfunctioning or dead neural cells with
fully functional ones may be a useful therapeutic strategy in treating many diseases and conditions of the central nervous system.
Our Proprietary and Novel Screening
Platform
Our
human neural stem cell lines form the foundation for functional cell-based assays used to screen for small molecule compounds that
can impact biologically relevant outcomes such as neurogenesis, synapse formation, and protection against toxic insults.
We
have developed over 300 unique stem cell lines representing multiple different regions of the developing brain and spinal cord
at multiple different time points in development, enabling the generation of physiologically relevant human neural cells for screening,
target validation, and mechanism-of-action studies. This platform provides us with a unique and powerful tool to identify new chemical
entities to treat a broad range of nervous system conditions. NSI-189 was discovered using our stem cell-based screening platform.
Intellectual Property
We have developed and maintain what we
believe is a strong portfolio of patents and patent applications that form the basis for our research and development efforts.
We own or exclusively license over 10 U.S. issued and pending patents and over 60 foreign issued and pending patents related to
our stem cell technologies for use in treating disease and injury. We additionally have 7 patent families related to small molecule
pharmaceuticals, including granted patents in the U.S. covering these pharmaceuticals as compositions of matter, granted patents
in the U.S. and abroad covering methods of manufacture and methods of identifying additional candidates, and granted patents and
pending applications in the U.S. and abroad covering indications for which these pharmaceuticals are useful. Our issued patents
have expiration dates ranging from 2017 through 2035. Two of our original patents covering methods and composition of matter associated
with our stem cell technologies expired in 2016. In our opinion the expiration of these patents is not material to our intellectual
property.
Operating Strategy
We generally employ
an outsourcing strategy where we outsource our preclinical and clinical development activities to contract research organizations
and academic partners. Manufacturing is also outsourced to organizations with approved facilities and manufacturing practices.
All non-critical corporate functions are outsourced as well. This model allows us to better manage cash on hand and minimize non-vital
expenditures. It also allows for us to operate with relatively fewer employees and lower fixed costs than that required by other
companies conducting similar business.
Employees
As of May 31, 2017, we had ten (10) full-time
employees. Of these full-time employees, seven (7) work on research and development and clinical operations and three (3) work
in administration. We also use the services of numerous outside consultants in business and scientific matters.
Risks Associated with our Business
Our business is subject to numerous risks,
as described under the heading “Risk Factors” contained in the applicable prospectus supplement and in any free writing
prospectuses we have authorized for use in connection with a specific offering, and under similar headings in the documents that
are incorporated by reference into this prospectus.
Our Corporate Information
We were incorporated in Delaware in 2001.
Our principal executive offices are located at 20271 Goldenrod Lane, Germantown, Maryland 20876, and our telephone number is (301)
366-4960. Our website is located at www.neuralstem.com.
We have not incorporated by reference into this report the information
in, or that can be accessed through, our website and you should not consider it to be a part of this report.
The Securities We May Offer
Under this prospectus, we may
offer shares of our common stock and preferred stock and/or warrants, rights or purchase contracts to purchase any of such securities,
either individually or in units, with a total value of up to $100,000,000, from time to time at prices and on terms to be determined
by market conditions at the time of the offering. This prospectus provides you with a general description of the securities we
may offer. Each time we offer a type or series of securities under this prospectus, we will provide a prospectus supplement that
will describe the specific amounts, prices and other important terms of the securities being offered.
The prospectus supplement may
also add, update or change information contained in this prospectus or in documents we have incorporated by reference into this
prospectus. We may sell the securities directly to investors or to or through agents, underwriters or dealers. We, and our agents
or underwriters, reserve the right to accept or reject all or part of any proposed purchase of securities. If we offer securities
through agents or underwriters, we will include in the applicable prospectus supplement:
|
|
·
|
the names of those agents or underwriters;
|
|
|
·
|
applicable fees, discounts and commissions to be paid to them;
|
|
|
·
|
details regarding over-allotment options, if any; and
|
|
|
·
|
the net proceeds to us.
|
This prospectus may not be
used to consummate a sale of any securities unless it is accompanied by a prospectus supplement.
RISK FACTORS
Investing in our securities involves a
high degree of risk. Before deciding whether to invest in our securities, you should consider carefully the risks and uncertainties
described under the heading “Risk Factors” contained in the applicable prospectus supplement and any related free writing
prospectus, and discussed under the section entitled “Risk Factors” contained in our most recent Annual Report on Form
10-K and in our most recent Quarterly Report on Form 10-Q, as well as any amendments thereto reflected in subsequent filings with
the SEC, which are incorporated by reference into this prospectus in their entirety, together with other information in this prospectus,
the documents incorporated by reference and any free writing prospectus that we may authorize for use in connection with this offering.
The risks described in these documents are not the only ones we face, but those that we consider to be material. There may be other
unknown or unpredictable economic, business, competitive, regulatory or other factors that could have material adverse effects
on our future results. Past financial performance may not be a reliable indicator of future performance, and historical trends
should not be used to anticipate results or trends in future periods. If any of these risks actually occurs, our business, financial
condition, results of operations or cash flow could be seriously harmed. This could cause the trading price of our common stock
to decline, resulting in a loss of all or part of your investment. Please also read carefully the section above entitled “Forward-Looking
Statements.”
USE OF PROCEEDS
We cannot assure you that we will receive
any proceeds in connection with securities which may be offered pursuant to this prospectus. Unless otherwise indicated in the
applicable prospectus supplement, we intend to use any net proceeds from the sale of securities under this prospectus for general
corporate purposes, including, but not limited to, repayment of existing indebtedness, working capital, intellectual property protection
and enforcement, capital expenditures, investments and acquisitions, including acquisitions of patent portfolios. We have not determined
the amounts we plan to spend on any of the areas listed above or the timing of these expenditures. As a result, our management
will have broad discretion to allocate the net proceeds, if any, we receive in connection with securities offered pursuant to this
prospectus for any purpose. Pending application of the net proceeds as described above, we may initially invest the net proceeds
in short-term, investment-grade, interest-bearing securities or apply them to the reduction of short-term indebtedness.
PLAN OF DISTRIBUTION
General Plan of Distribution
We may offer securities under this prospectus
from time to time pursuant to underwritten public offerings, negotiated transactions, block trades or a combination of these methods.
We may sell the securities (i) through underwriters or dealers, (ii) through agents or (iii) directly to one or more purchasers,
or through a combination of such methods. We may distribute the securities from time to time in one or more transactions at:
|
|
·
|
a fixed price or prices, which may be changed from time to time;
|
|
|
·
|
market prices prevailing at the time of sale;
|
|
|
·
|
prices related to the prevailing market prices; or
|
We may directly solicit offers to purchase
the securities being offered by this prospectus. We may also designate agents to solicit offers to purchase the securities from
time to time. We will name in a prospectus supplement any underwriter or agent involved in the offer or sale of the securities.
If we utilize a dealer in the sale of the
securities being offered by this prospectus, we will sell the securities to the dealer, as principal. The dealer may then resell
the securities to the public at varying prices to be determined by the dealer at the time of resale.
If we utilize an underwriter in the sale
of the securities being offered by this prospectus, we will execute an underwriting agreement with the underwriter at the time
of sale, and we will provide the name of any underwriter in the prospectus supplement which the underwriter will use to make resales
of the securities to the public. In connection with the sale of the securities, we, or the purchasers of the securities for whom
the underwriter may act as agent, may compensate the underwriter in the form of underwriting discounts or commissions. The underwriter
may sell the securities to or through dealers, and the underwriter may compensate those dealers in the form of discounts, concessions
or commissions.
With respect to underwritten public offerings,
negotiated transactions and block trades, we will provide in the applicable prospectus supplement information regarding any compensation
we pay to underwriters, dealers or agents in connection with the offering of the securities, and any discounts, concessions or
commissions allowed by underwriters to participating dealers. Underwriters, dealers and agents participating in the distribution
of the securities may be deemed to be underwriters within the meaning of the Securities Act of 1933, as amended, or the Securities
Act, and any discounts and commissions received by them and any profit realized by them on resale of the securities may be deemed
to be underwriting discounts and commissions. We may enter into agreements to indemnify underwriters, dealers and agents against
civil liabilities, including liabilities under the Securities Act, or to contribute to payments they may be required to make in
respect thereof.
If so indicated in the applicable prospectus
supplement, we will authorize underwriters or other persons acting as our agents to solicit offers by certain institutions to purchase
securities from us pursuant to delayed delivery contracts providing for payment and delivery on the date stated in the prospectus
supplement. Each contract will be for an amount not less than, and the aggregate amount of securities sold pursuant to such contracts
shall not be less nor more than, the respective amounts stated in the prospectus supplement. Institutions with whom the contracts,
when authorized, may be made include commercial and savings banks, insurance companies, pension funds, investment companies, educational
and charitable institutions and other institutions, but shall in all cases be subject to our approval. Delayed delivery contracts
will not be subject to any conditions except that:
|
|
·
|
the purchase by an institution of the securities covered under that contract shall not at the time
of delivery be prohibited under the laws of the jurisdiction to which that institution is subject; and
|
|
|
·
|
if the securities are also being sold to underwriters acting as principals for their own account,
the underwriters shall have purchased such securities not sold for delayed delivery. The underwriters and other persons acting
as our agents will not have any responsibility in respect of the validity or performance of delayed delivery contracts.
|
Certain underwriters may use this prospectus
and any accompanying prospectus supplement for offers and sales related to market-making transactions in the securities. These
underwriters may act as principal or agent in these transactions, and the sales will be made at prices related to prevailing market
prices at the time of sale. Any underwriters involved in the sale of the securities may qualify as “underwriters” within
the meaning of Section 2(a)(11) of the Securities Act. In addition, the underwriters’ commissions, discounts or concessions
may qualify as underwriters’ compensation under the Securities Act and the rules of the Financial Industry Regulatory Authority,
Inc., or FINRA.
Shares of our common stock sold pursuant
to the registration statement of which this prospectus is a part will be authorized for quotation and trading on the NASDAQ Capital
Market. The applicable prospectus supplement will contain information, where applicable, as to any other listing, if any, on the
NASDAQ Capital Market or any securities market or other securities exchange of the securities covered by the prospectus supplement.
We can make no assurance as to the liquidity of or the existence of trading markets for any of the securities.
In order to facilitate the offering of
the securities, certain persons participating in the offering may engage in transactions that stabilize, maintain or otherwise
affect the price of the securities. This may include over-allotments or short sales of the securities, which involve the sale by
persons participating in the offering of more securities than we sold to them. In these circumstances, these persons would cover
such over-allotments or short positions by making purchases in the open market or by exercising their over-allotment option. In
addition, these persons may stabilize or maintain the price of the securities by bidding for or purchasing the applicable security
in the open market or by imposing penalty bids, whereby selling concessions allowed to dealers participating in the offering may
be reclaimed if the securities sold by them are repurchased in connection with stabilization transactions. The effect of these
transactions may be to stabilize or maintain the market price of the securities at a level above that which might otherwise prevail
in the open market. These transactions may be discontinued at any time.
The underwriters, dealers and agents may
engage in other transactions with us, or perform other services for us, in the ordinary course of their business.
DESCRIPTION OF CAPITAL STOCK
The following is a summary of our capital
stock and provisions of our restated certificate of incorporation and restated by-laws, as they are in effect as of the date of
this prospectus. For more detailed information, please see our amended and restated certificate of incorporation and restated bylaws,
which are filed with the Securities and Exchange Commission as exhibits to the registration statement of which this prospectus
forms a part.
We are authorized to issue 300,000,000
shares of common stock, par value $0.01 per share, and 7,000,000 shares of preferred stock, par value $0.01 per share. As of May
31, 2017, we had:
|
|
·
|
11,911,877 shares of common stock outstanding held of record by 295 stockholders, which does not
include stockholders who hold their shares in “street name”; and
|
|
|
·
|
1,000,000 shares
of our Series A 4.5% Convertible Preferred
Stock which is convertible into 3,887,387 shares of common stock subject to certain ownership restrictions.
|
Common Stock
Holders of common stock are entitled to
one vote for each share held of record on all matters submitted to a vote of the stockholders, subject to the holder of our Series
A 4.5% Convertible Preferred Stock having the ability to appoint one director, and do not have cumulative voting rights. Subject
to preferences that may be applicable to any outstanding shares of preferred stock, holders of common stock are entitled to receive
ratably such dividends, if any, as may be declared from time to time by our board of directors out of funds legally available for
dividend payments. All shares of common stock outstanding as of the date of this prospectus are fully paid and nonassessable. The
holders of common stock have no preferences or rights of conversion, exchange, pre-emption or other subscription rights. There
are no redemption or sinking fund provisions applicable to the common stock. In the event of any liquidation, dissolution or winding-up
of our affairs, holders of common stock will be entitled to share ratably in our assets that are remaining after payment or provision
for payment of all of our debts and obligations and after liquidation payments to holders of outstanding shares of preferred stock,
if any.
Preferred Stock
Our board of directors has the authority,
without action by our stockholders, to designate and issue up to an additional 6,000,000 shares of preferred stock in one or more
series and to designate the rights, preferences, and limitations of all such series, any or all of which may be superior to the
rights of our common stock. It is not possible to state the actual effect of the issuance of any shares of preferred stock upon
the rights of the holders of common stock until our board of directors determines the specific rights of the holders of preferred
stock. However, effects of the issuance of preferred stock include restricting dividends on our common stock, diluting the voting
power of our common stock, impairing the liquidation rights of our common stock, and making it more difficult for a third party
to acquire us, which could have the effect of discouraging a third party from acquiring, or deterring a third party from paying
a premium to acquire, a majority of our outstanding voting stock. We have no present plans to issue any additional shares of our
preferred stock.
Series A 4.5% Convertible Preferred Stock
We currently have outstanding 1,000,000
shares of Series A 4.5% Convertible Preferred Stock with a stated value of $12.7895 per share and which are immediately convertible
into an aggregate of 3,887,387 shares of common stock, subject to a beneficial ownership limitation not allowing the holder to
have greater than a 19.99% voting interest. The Series A Preferred Stock has no provisions regarding subsequent securities issuances
or so called “price protection provisions.” The holders of Series A Preferred Stock shall be entitled receive 4.5%
dividends in cash or additional shares of Series A Preferred Stock if and when declared by the Company’s board of directors
in preference to the payment of any dividends on the Common Stock. The holders of Series A Preferred Stock shall have no voting
rights but shall be entitled to appoint one (1) member to our board of directors. This right to appoint a member of the board of
directors will terminate when there are less than 200,000 shares of Series A Preferred Stock outstanding.
Additionally, until the Company’s
2019 annual meeting of stockholders, subject to certain limitations, the holder of the Series A Preferred Stock has agreed not
to solicit proxies, seek to remove any member of the board of directors, contest any of our solicitations, make stockholder proposals,
vote its securities against the recommendations of our board of directors, participate in any group with respect to its voting
stock, seek to waive, amend or modify our certificate of incorporation or bylaws, or effect or participate in any tender offer;
or business combination; or acquisition or restructuring or recapitalization of the Company.
Preferred Stock in General
Our board of directors may, without further
action by our stockholders, from time to time, direct the issuance of shares of preferred stock in series and may, at the time
of issuance, determine the rights, preferences and limitations of each series, including voting rights, dividend rights and redemption
and liquidation preferences. Satisfaction of any dividend preferences of outstanding shares of preferred stock would reduce the
amount of funds available for the payment of dividends on shares of our common stock. Holders of shares of preferred stock may
be entitled to receive a preference payment in the event of any liquidation, dissolution or winding-up of our company before any
payment is made to the holders of shares of our common stock. In some circumstances, the issuance of shares of preferred stock
may render more difficult or tend to discourage a merger, tender offer or proxy contest, the assumption of control by a holder
of a large block of our securities or the removal of incumbent management. Upon the affirmative vote of our board of directors,
without stockholder approval, we may issue shares of preferred stock with voting and conversion rights which could adversely affect
the holders of shares of our common stock.
If we offer a specific series of preferred
stock under this prospectus, we will describe the terms of the preferred stock in the prospectus supplement for such offering and
will file a copy of the certificate establishing the terms of the preferred stock with the SEC. To the extent required, this description
will include:
|
|
·
|
the title and stated value;
|
|
|
·
|
the number of shares offered, the liquidation preference, if any, per share and the purchase price;
|
|
|
·
|
the dividend rate(s), period(s) and/or payment date(s), or method(s) of calculation for such dividends;
|
|
|
·
|
whether dividends will be cumulative or non-cumulative and, if cumulative, the date from which
dividends will accumulate;
|
|
|
·
|
the procedures for any auction and remarketing, if any;
|
|
|
·
|
the provisions for a sinking fund, if any;
|
|
|
·
|
the provisions for redemption, if applicable;
|
|
|
·
|
any listing of the preferred stock on any securities exchange or market;
|
|
|
·
|
whether the preferred stock will be convertible into our common stock, and, if applicable, the
conversion price (or how it will be calculated) and conversion period;
|
|
|
·
|
whether the preferred stock will be exchangeable into debt securities, and, if applicable, the
exchange price (or how it will be calculated) and exchange period;
|
|
|
·
|
voting rights, if any, of the preferred stock;
|
|
|
·
|
a discussion of any material and/or special U.S. federal income tax considerations applicable to
the preferred stock;
|
|
|
·
|
the relative ranking and preferences of the preferred stock as to dividend rights and rights upon
liquidation, dissolution or winding up of the affairs of the Company; and
|
|
|
·
|
any material limitations on issuance of any class or series of preferred stock ranking pari passu
with or senior to the series of preferred stock as to dividend rights and rights upon liquidation, dissolution or winding up of
the Company.
|
Transfer Agent and Registrar
The transfer agent and registrar for our
common stock is American Stock Transfer & Trust Company. We act as the transfer agent and registrar for out Series A 4.5% Convertible
Preferred Stock. In the event we issue an preferred stock in the future pursuant to this prospectus, the transfer agent and registrar
for such preferred stock will be set forth in the applicable prospectus supplement.
Anti-Takeover Effects of Some Provisions of Delaware Law
Provisions of Delaware law could make the
acquisition of our company through a tender offer, a proxy contest or other means more difficult and could make the removal of
incumbent officers and directors more difficult. We expect these provisions to discourage coercive takeover practices and inadequate
takeover bids and to encourage persons seeking to acquire control of our company to first negotiate with our board of directors.
We believe that the benefits provided by our ability to negotiate with the proponent of an unfriendly or unsolicited proposal outweigh
the disadvantages of discouraging these proposals. We believe the negotiation of an unfriendly or unsolicited proposal could result
in an improvement of its terms.
We are subject to Section 203 of the
Delaware General Corporation Law, an anti-takeover law. In general, Section 203 prohibits a publicly held Delaware corporation
from engaging in a “business combination” with an “interested stockholder” for a period of three years
following the date the person became an interested stockholder, unless:
|
|
·
|
Prior to the date of the transaction, the board of directors of the corporation approved either
the business combination or the transaction which resulted in the stockholder becoming an interested stockholder;
|
|
|
·
|
The stockholder owned at least 85% of the voting stock of the corporation outstanding at the time
the transaction commenced, excluding for purposes of determining the number of shares outstanding (a) shares owned by persons who
are directors and also officers, and (b) shares owned by employee stock plans in which employee participants do not have the right
to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or
|
|
|
·
|
On or subsequent to the date of the transaction, the business combination is approved by the board
and authorized at an annual or special meeting of stockholders, and not by written consent, by the affirmative vote of at least
two-thirds of the outstanding voting stock that is not owned by the interested stockholder.
|
Generally, a “business combination”
includes a merger, asset or stock sale, or other transaction resulting in a financial benefit to the interested stockholder. An
“interested stockholder” is a person who, together with affiliates and associates, owns or, within three years prior
to the determination of interested stockholder status, did own 15% or more of a corporation’s outstanding voting securities.
We expect the existence of this provision to have an anti-takeover effect with respect to transactions our board of directors does
not approve in advance. We also anticipate that Section 203 may also discourage attempts that might result in a premium over
the market price for the shares of common stock held by stockholders.
Anti-Takeover Effects of Provisions of Our Charter Documents
Our amended and restated bylaws provides
for our board of directors to be divided into three classes serving staggered terms. Approximately one-third of the board of directors
will be elected each year. The provision for a classified board could prevent a party who acquires control of a majority of the
outstanding voting stock from obtaining control of the board of directors until the second annual stockholders meeting or longer,
following the date the acquirer obtains the controlling stock interest. The classified board provision could discourage a potential
acquirer from making a tender offer or otherwise attempting to obtain control of our company and could increase the likelihood
that incumbent directors will retain their positions. Our amended and restated bylaws provides any director or the entire Board
may be removed from office at any time, with or without cause, by the affirmative vote of the holders of at least a majority of
the voting power of the issued and outstanding shares of capital stock of the corporation then entitled to vote in the election
of directors.
Our amended and restated bylaws establish
an advance notice procedure for stockholder proposals to be brought before an annual meeting of our stockholders, including proposed
nominations of persons for election to the board of directors. At an annual meeting, stockholders may only consider proposals or
nominations specified in the notice of meeting or brought before the meeting by or at the direction of the board of directors.
Stockholders may also consider a proposal or nomination by a person who was a stockholder of record on the record date for the
meeting, who is entitled to vote at the meeting and who has given to our Secretary timely written notice, in proper form, of his
or her intention to bring that business before the meeting. The amended and restated bylaws do not give the board of directors
the power to approve or disapprove stockholder nominations of candidates or proposals regarding other business to be conducted
at a special or annual meeting of the stockholders. However, our bylaws may have the effect of precluding the conduct of business
at a meeting if the proper procedures are not followed. These provisions may also discourage or deter a potential acquirer from
conducting a solicitation of proxies to elect the acquirer’s own slate of directors or otherwise attempting to obtain control
of our company.
Our amended and restated bylaws provide
that only our board of directors, the chairperson of the board or the chief executive officer (or president, in the absence of
a chief executive officer) or holders of more than twenty percent (20%) of the total voting power of the outstanding shares of
capital stock may call a special meeting of stockholders. The restriction on the ability of stockholders to call a special meeting
means that a proposal to replace the board also could be delayed until the next annual meeting.
Limitations on Liability and Indemnification
of Officers and Directors
Our amended restated certificate of incorporation
limits the liability of our officers and directors to the fullest extent permitted by the Delaware General Corporation Law, and
our restated certificate of incorporation and restated bylaws provide for indemnification of our officers and directors to the
fullest extent permitted by such law.
DESCRIPTION OF WARRANTS
As of May 31, 2017, there were warrants
to purchase 2,594,602 shares of our common stock outstanding at a weighted-average exercise price of $17.32 per share and expiration
dates between 2017 and 2022. This amount is comprised of the following warrants:
|
|
Range of
Exercise
Prices
|
|
Number of
Warrants
Outstanding
|
|
Range of Expiration Dates
|
|
|
|
$3.25 - $3.90
|
|
|
911,556
|
|
|
May 2021 - July 2021
|
|
|
|
$5.80 - $6.50
|
|
|
318,113
|
|
|
June 2017 - March 2018
|
|
|
|
$12.80 - $12.90
|
|
|
39,296
|
|
|
January 2022
|
|
|
|
$13.20 - $13.30
|
|
|
314,246
|
|
|
August 2017
|
|
|
|
$16.20 - $16.30
|
|
|
174,544
|
|
|
March 2020
|
|
|
|
$18.60 - $19.80
|
|
|
12,309
|
|
|
March 2018 - June 2018
|
|
|
|
$22.10 - $27.90
|
|
|
153,755
|
|
|
March 2019 - January 2021
|
|
|
|
$34.50 - $39.00
|
|
|
164,114
|
|
|
November 2017 - October 2019
|
|
|
|
$39.10 - $39.20
|
|
|
230,772
|
|
|
October 2020 - October 2021
|
|
|
|
$47.30 - $52.20
|
|
|
275,897
|
|
|
January 2019 - July 2019
|
|
|
|
|
|
|
2,594,602
|
|
|
|
|
There is no established market for any
of our warrants.
General
We may issue warrants to purchase shares
of our common stock and/or preferred stock in one or more series together with other securities or separately,
as described in the applicable prospectus supplement. Below is a description of certain general terms and provisions of the warrants
that we may offer. Particular terms of the warrants will be described in the warrant agreements and the prospectus supplement relating
to the warrants.
The applicable prospectus supplement will
contain, where applicable, the following terms of and other information relating to the warrants:
|
|
·
|
the specific designation and aggregate number of, and the price at which we will issue, the warrants;
|
|
|
·
|
the currency or currency units in which the offering price, if any, and the exercise price are
payable;
|
|
|
·
|
the designation, amount and terms of the securities purchasable upon exercise of the warrants;
|
|
|
·
|
if applicable, the exercise price for shares of our common stock and the number of shares of common
stock to be received upon exercise of the warrants;
|
|
|
·
|
if applicable, the exercise price for shares of our preferred stock, the number of shares of preferred
stock to be received upon exercise, and a description of that series of our preferred stock;
|
|
|
·
|
the date on which the right to exercise the warrants will begin and the date on which that right
will expire or, if you may not continuously exercise the warrants throughout that period, the specific date or dates on which you
may exercise the warrants;
|
|
|
·
|
whether the warrants will be issued in fully registered form or bearer form, in definitive or global
form or in any combination of these forms, although, in any case, the form of a warrant included in a unit will correspond to the
form of the unit and of any security included in that unit;
|
|
|
·
|
any applicable material U.S. federal income tax consequences;
|
|
|
·
|
if applicable, the identity of the warrant agent for the warrants and of any other depositaries, execution or
paying agents, transfer agents, registrars or other agents;
|
|
|
·
|
the proposed listing, if any, of the warrants or any securities purchasable upon exercise of the
warrants on any securities exchange;
|
|
|
·
|
if applicable, the date from and after which the warrants and the common stock and/or
preferred stock will be separately transferable;
|
|
|
·
|
if applicable, the minimum or maximum amount of the warrants that may be exercised at any one time;
|
|
|
·
|
information with respect to book-entry procedures, if any;
|
|
|
·
|
the anti-dilution provisions of the warrants, if any;
|
|
|
·
|
any redemption or call provisions;
|
|
|
·
|
whether the warrants may be sold separately or with other securities as parts of units; and
|
|
|
·
|
any additional terms of the warrants, including terms, procedures and limitations relating to the
exchange and exercise of the warrants.
|
Transfer Agent and Registrar
The transfer agent and registrar for any
warrants we offer will be set forth in the applicable prospectus supplement.
DESCRIPTION OF RIGHTS
General
We may issue rights to our stockholders to purchase shares of our
common stock, preferred stock or the other securities described in this prospectus. We may offer rights separately or together
with one or more additional rights, preferred stock, common stock, warrants or purchase contracts, or any combination of those
securities in the form of units, as described in the applicable prospectus supplement. Each series of rights will be issued under
a separate rights agreement. The following description sets forth certain general terms and provisions of the rights to which any
prospectus supplement may relate. The particular terms of the rights to which any prospectus supplement may relate and the extent,
if any, to which the general provisions may apply to the rights so offered will be described in the applicable prospectus supplement.
To the extent that any particular terms of the rights, rights agreement or rights certificates described in a prospectus supplement
differ from any of the terms described below, then the terms described below will be deemed to have been superseded by that prospectus
supplement. We encourage you to read the applicable rights agreement and rights certificate for additional information before you
decide whether to purchase any of our rights.
We will provide in a prospectus supplement
the following terms of the rights being issued:
|
|
·
|
the date of determining the stockholders entitled to the rights distribution;
|
|
|
·
|
the aggregate number of shares of common stock, preferred stock or other securities purchasable
upon exercise of the rights;
|
|
|
·
|
the aggregate number of rights issued;
|
|
|
·
|
whether the rights are transferrable and the date, if any, on and after which the rights may be
separately transferred;
|
|
|
·
|
the date on which the right to exercise the rights will commence, and the date on which the right
to exercise the rights will expire;
|
|
|
·
|
the method by which holders of rights will be entitled to exercise;
|
|
|
·
|
the conditions to the completion of the offering, if any;
|
|
|
·
|
the withdrawal, termination and cancellation rights, if any;
|
|
|
·
|
whether there are any backstop or standby purchaser or purchasers and the terms of their commitment,
if any;
|
|
|
·
|
whether stockholders are entitled to oversubscription rights, if any;
|
|
|
·
|
any applicable U.S. federal income tax considerations; and
|
|
|
·
|
any other terms of the rights, including terms, procedures and limitations relating to the distribution,
exchange and exercise of the rights, as applicable.
|
Each right will entitle the holder of rights
to purchase for cash the principal amount of shares of common stock, preferred stock or other securities at the exercise price
provided in the applicable prospectus supplement. Rights may be exercised at any time up to the close of business on the expiration
date for the rights provided in the applicable prospectus supplement.
Holders may exercise rights as described in the applicable prospectus
supplement. Upon receipt of payment and the rights certificate properly completed and duly executed at the corporate trust office
of a rights agent, if applicable, or any other office indicated in the prospectus supplement, we will, as soon as practicable,
forward the shares of common stock, preferred stock or other securities, as applicable, purchasable upon exercise of the rights.
If less than all of the rights issued in any rights offering are exercised, we may offer any unsubscribed securities directly to
persons other than stockholders, to or through agents, underwriters or dealers or through a combination of such methods, including
pursuant to standby arrangements, as described in the applicable prospectus supplement.
Rights
Agent
If applicable, the rights agent for any rights we offer will be
set forth in the applicable prospectus supplement.
DESCRIPTION OF PURCHASE CONTRACTS
We may issue purchase contracts, including
contracts obligating holders to purchase from us, and for us to sell to holders, a specific or variable number of our
shares of common stock, preferred stock, warrants or rights, or securities of an entity unaffiliated with us, or any combination
of the above, at a future date or dates. Alternatively, the purchase contracts may obligate us to purchase from holders, and obligate
holders to sell to us, a specific or variable number of our shares of common stock, preferred stock, warrants,
rights or other property, or any combination of the above. The price of the securities or other property subject to the purchase
contracts may be fixed at the time the purchase contracts are issued or may be determined by reference to a specific formula described
in the purchase contracts. We may issue purchase contracts separately or as a part of units each consisting of a purchase contract
and one or more of our other securities described in this prospectus or securities of third parties, including U.S. Treasury securities,
securing the holder’s obligations under the purchase contract. The purchase contracts may require us to make periodic payments
to holders or vice versa and the payments may be unsecured or pre-funded on some basis. The purchase contracts may require holders
to secure the holder’s obligations in a manner specified in the applicable prospectus supplement.
The applicable prospectus supplement will
describe the terms of any purchase contracts in respect of which this prospectus is being delivered, including, to the extent applicable,
the following:
|
|
·
|
whether the purchase contracts obligate the holder or us to purchase or sell, or both purchase
and sell, the securities subject to purchase under the purchase contract, and the nature and amount of each of those securities,
or the method of determining those amounts;
|
|
|
·
|
whether the purchase contracts are to be prepaid;
|
|
|
·
|
whether the purchase contracts are to be settled by delivery, or by reference or linkage to the
value, performance or level of the securities subject to purchase under the purchase contract;
|
|
|
·
|
any acceleration, cancellation, termination or other provisions relating to the settlement of the
purchase contracts;
|
|
|
·
|
any applicable U.S. federal income tax considerations; and
|
|
|
·
|
whether the purchase contracts will be issued in fully registered or global form.
|
The preceding description sets forth certain
general terms and provisions of the purchase contracts to which any prospectus supplement may relate. The particular terms of the
purchase contracts to which any prospectus supplement may relate and the extent, if any, to which the general provisions may apply
to the purchase contracts so offered will be described in the applicable prospectus supplement. To the extent that any particular
terms of the purchase contracts described in a prospectus supplement differ from any of the terms described above, then the terms
described above will be deemed to have been superseded by that prospectus supplement. We encourage you to read the applicable purchase
contract for additional information before you decide whether to purchase any of our purchase contracts.
DESCRIPTION OF UNITS
The following description, together with
the additional information that we include in any applicable prospectus supplements summarizes the material terms and provisions
of the units that we may offer under this prospectus. While the terms we have summarized below will apply generally to any units
that we may offer under this prospectus, we will describe the particular terms of any series of units in more detail in the applicable
prospectus supplement. The terms of any units offered under a prospectus supplement may differ from the terms described below.
We will incorporate by reference from reports
that we file with the SEC, the form of unit agreement that describes the terms of the series of units we are offering, and any
supplemental agreements, before the issuance of the related series of units. The following summaries of material terms and provisions
of the units are subject to, and qualified in their entirety by reference to, all the provisions of the unit agreement and any
supplemental agreements applicable to a particular series of units. We urge you to read the applicable prospectus supplements related
to the particular series of units that we may offer under this prospectus, as well as any related free writing prospectuses and
the complete unit agreement and any supplemental agreements that contain the terms of the units.
General
We may issue units consisting of common
stock, preferred stock, warrants, rights or purchase contacts for the purchase of common stock and/or preferred stock in one or
more series or in any combination thereof. Each unit will be issued so that the holder of the unit is also the holder of each security
included in the unit. Thus, the holder of a unit will have the rights and obligations of a holder of each security included in
the unit. The unit agreement under which a unit is issued may provide that the securities included in the unit may not be held
or transferred separately, at any time or at any time before a specified date.
We will describe in the applicable prospectus
supplement the terms of the series of units being offered, including:
|
|
·
|
the designation and terms of the units and of the securities comprising the units, including whether
and under what circumstances those securities may be held or transferred separately;
|
|
|
·
|
any provisions of the governing unit agreement that differ from those described below; and
|
|
|
·
|
any provisions for the issuance, payment, settlement, transfer or exchange of the units or of the
securities comprising the units.
|
The provisions described in this section,
as well as those set forth in any prospectus supplement or as described under “Description of Common Stock,” “Description
of Preferred Stock,” “Description of Warrants,” “Description of Rights” and “Description of
Purchase Contracts” will apply to each unit, as applicable, and to any common stock, preferred stock, warrant, right or purchase
contract included in each unit, as applicable.
Unit Agent
If applicable, the name and address of the unit agent for any units
we offer will be set forth in the applicable prospectus supplement.
Issuance in Series
We may issue units in such amounts and
in such numerous distinct series, if any, as we determine.
Enforceability of Rights by Holders of Units
If applicable, each unit agent will act solely as our agent under
the applicable unit agreement and will not assume any obligation or relationship of agency or trust with any holder of any unit.
A unit agent may act as unit agent for more than one series of units. If applicable, a unit agent will have no duty or responsibility
in case of any default by us under the applicable unit agreement or unit, including any duty or responsibility to initiate any
proceedings at law or otherwise, or to make any demand upon us. Any holder of a unit may, without the consent of the related unit
agent or the holder of any other unit, enforce by appropriate legal action its rights as holder under any security included in
the unit.
LEGAL MATTERS
The validity of the issuance of the securities
offered hereby will be passed upon for us by the Silvestre Law Group, P.C., Westlake Village, California. The Silvestre Law Group,
P.C. or its affiliates or principals own
4,154 shares
of our common stock and 46,156
of our common stock purchase warrants.
EXPERTS
The financial statements incorporated
in this prospectus by reference from our Annual Report on Form 10-K have been audited by Stegman & Company, our prior
independent registered public accounting firm, with regarding to the year ended December 31, 2015 and Dixon Hughes Goodman LLP,
our current independent registered public accounting firm, for the year ended December 31, 2016, as stated in their respective
reports, which are each incorporated herein by reference. Such financial statements have been so incorporated in reliance
upon the report of such firm given upon their authority as experts in accounting and auditing.
WHERE YOU CAN FIND MORE INFORMATION
We are a public company and file annual,
quarterly and current reports, proxy statements and other information with the SEC. You may obtain copies of our public filings,
as noted in the paragraph below or by writing or telephoning us at:
Neuralstem, Inc.
Attn: Investor Relations
20271 Goldenrod Lane
Germantown, Maryland 20876
Phone: (301)-366-4960
We file annual, quarterly and other reports,
proxy statements and other information with the SEC. Our SEC filings are available to the public over the Internet at the SEC’s
website at
http://www.sec.gov
. You may also read and copy any document we file at the SEC’s Public Reference Room
at 100 F Street, NE, Washington, D.C. 20549. Please call the SEC at 1-800-SEC-0330 for further information on the Public Reference
Room. You can also inspect reports, proxy statements and other information about us at the offices of the National Association
of Securities Dealers, Reports Section, 1735 K Street, N.W., Washington, D.C. 20006. We maintain a website at http://www.neuralstem.com.
Information contained in or accessible through our website does not constitute a part of this prospectus.
This prospectus supplement and the accompanying
prospectus are part of a registration statement on Form S-3 that we filed with the SEC registering the securities that may
be offered and sold hereunder. The registration statement, including exhibits thereto, contains additional relevant information
about us and these securities that, as permitted by the rules and regulations of the SEC, we have not included in this prospectus
supplement or the accompanying prospectus. A copy of the registration statement can be obtained at the address set forth above.
You should read the registration statement for further information about us and these securities.
INCORPORATION OF DOCUMENTS BY REFERENCE
The SEC permits us to “incorporate
by reference” the information contained in documents we file with the SEC, which means that we can disclose important information
to you by referring you to those documents rather than by including them in this prospectus supplement or the accompanying prospectus.
Information that is incorporated by reference is considered to be part of this prospectus supplement, and you should read it with
the same care that you read this prospectus supplement. Later information that we file with the SEC will automatically update and
supersede the information that is either contained, or incorporated by reference, in this prospectus supplement, and will be considered
to be a part of this prospectus supplement from the date those documents are filed.
We incorporate by reference into this prospectus
supplement the following documents and information filed with the SEC:
|
|
·
|
Our Annual Report on Form 10-K filed with the SEC on March 23, 2017, for the year ended December
31, 2016;
|
|
|
·
|
Our Quarterly Report on Form 10-Q filed with the SEC on May 10, 2017, for the three month period
ended March 31, 2017;
|
|
|
·
|
Our Definitive Proxy Statement on Form 14A for our 2017 Annual Meeting of Stockholders, filed with
the SEC on May 1, 2017;
|
|
|
·
|
Our Current Reports on Form 8-K filed with the SEC on January 6, February 16 and 22, March 20 and 31,
April 13 and 19, and May 4, 18 and 24, 2017 (excluding any information furnished in such reports under Item 2.02, Item 7.01 or
Item 9.01); and
|
|
|
·
|
the description of our common stock and related rights contained in our registration statement
on Form 8-A (File No. 001-33672), filed with the Commission on July 1, 2015, including any amendment or report filed for the purpose
of updating such description.
|
We also incorporate by reference into this
prospectus supplement all additional documents that we file with the SEC under the terms of Section 13(a), 13(c), 14 or 15(d)
of the Securities Exchange Act of 1934 that are made after the date of this prospectus supplement and before the termination of
the offering of securities offered by this prospectus supplement. We are not, however, incorporating, in each case, any documents
or information that we are deemed to furnish and not file in accordance with SEC rules.
You may request a copy of any of the documents
incorporated by reference into this prospectus supplement, at no cost, by writing or telephoning us at the following address: Neuralstem,
Inc., Attn: Investor Relations, 20271 Goldenrod Lane, Germantown, Maryland 20876 Phone: (301) 366-4960.
$100,000,000
NEURALSTEM, INC.
COMMON STOCK
PREFERRED STOCK
WARRANTS
RIGHTS
PURCHASE CONTRACTS
UNITS
PROSPECTUS
June 26,
2017
3,000,000 Shares of Common Stock
PROSPECTUS SUPPLEMENT
Placement Agent
H.C. Wainwright & Co.
October 25, 2018
Neuralstem (NASDAQ:CUR)
Historical Stock Chart
From Jan 2025 to Feb 2025
Neuralstem (NASDAQ:CUR)
Historical Stock Chart
From Feb 2024 to Feb 2025
